Materiały źródłowe

• #1 Malignant peripheral nerve sheath tumors – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/malignant-peripheral-nerve-sheath-tumors/symptoms-causes/syc-20362603

  Malignant peripheral nerve sheath tumors are rare cancers that start in the lining of the nerves. […] It’s not clear what causes most malignant peripheral nerve sheath tumors. […] Experts know that these cancers begin when a cell in the lining around a nerve gets changes in its DNA. A cell’s DNA holds the instructions that tell a cell what to do. The changes tell the cells to make more cells quickly. These cells continue to live when healthy cells die as part of their life cycle. […] The cells then can form a mass called a tumor. The tumor can grow into and kill healthy body tissue. In time, the cells can spread to other parts of the body.

• #2 Malignant Peripheral Nerve Sheath Tumor (MPNST)

  https://my.clevelandclinic.org/health/diseases/malignant-peripheral-nerve-sheath-tumor-mpnst

  Malignant peripheral nerve sheath tumors (MPNSTs) affect nerves that manage your muscles and sense of touch. In MPNST, cells that make up nerves protective shield become cancerous and multiply to develop tumors. Its a very rare cancer that grows very quickly. […] People who have the inherited disorder neurofibromatosis type 1 (NF1) often develop MPNST. Between 25% and 50% of people who have a malignant peripheral nerve sheath tumor also have NF1. […] Studies show neurofibromatosis type 1 accounts for 50% of malignant peripheral nerve sheath tumors. Other causes include: […] Genetic mutations: Researchers have found several different genetic mutations that turn normal nerve sheath cells into abnormal cells that multiply and create tumors. […] Certain neurofibromas: People with plexiform neurofibroma have an increased risk for MPNST.

• #3 Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8774267/

  Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas (STS) with nerve sheath differentiation and a tendency to metastasize. Although occurring at an incidence of 0.001% in the general population, they are relatively common in individuals with neurofibromatosis type 1 (NF1), for whom the lifetime risk approaches 10%. […] MPNSTs may arise de novo from a peripheral nerve OR as a malignant transformation of a pre-existing benign nerve sheath tumor especially neurofibromas. […] MPNSTs are most often characterized by the second variety of mutations specifically by loss of function of the tumor suppressor gene NF1. […] Although bi-allelic NF1 inactivation or mutation appears necessary for MPNST development, it does not seem sufficient. […] Therefore, one potential model for MPNST development proposes that bi-allelic NF1 loss occurs in nerve-sheath precursor cells, resulting in benign neurofibroma formation.

• #4 Mayo Clinic Health Library – Malignant peripheral nerve sheath tumors | Swiss Medical Network

  https://www.swissmedical.net/en/healtcare-library/con-20313998

  It’s not clear what causes most malignant peripheral nerve sheath tumors. […] Experts know that these cancers begin when a cell in the lining around a nerve gets changes in its DNA. A cell’s DNA holds the instructions that tell a cell what to do. The changes tell the cells to make more cells quickly. These cells continue to live when healthy cells die as part of their life cycle. […] The cells then can form a mass called a tumor. The tumor can grow into and kill healthy body tissue. In time, the cells can spread to other parts of the body.

• #5 Malignant peripheral nerve sheath tumour (MPNST) | Soft tissue sarcoma | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/soft-tissue-sarcoma/types/malignant-schwannoma

  Malignant peripheral nerve sheath tumours are a type of peripheral nerve sheath tumour. These cancers begin in the layer (nerve sheath) that cover the peripheral nerves. MPNST are rare in the general population. It can happen in people with neurofibromatosis type 1(NF1). […] Malignant peripheral nerve sheath tumours can be difficult to treat. […] Malignant peripheral nerve sheath tumours don’t respond very well to chemotherapy. Chemotherapy may be used to try to shrink the tumour or slow its growth, but it is usually unlikely to cure it. […] A malignant peripheral nerve sheath tumour can come back in the same place. This is called local recurrence.

• #6 Malignant peripheral nerve sheath tumor – Wikipedia

  https://en.wikipedia.org/wiki/Malignant_peripheral_nerve_sheath_tumor

  A malignant peripheral nerve sheath tumor (MPNST) is a form of cancer of the connective tissue surrounding peripheral nerves. […] About half the cases are diagnosed in people with neurofibromatosis; the lifetime risk for an MPNST in patients with neurofibromatosis type 1 is 813%. […] Soft tissue sarcomas have been linked within families, so it is hypothesized that neurofibrosarcoma may be genetic, although researchers still do not know the exact cause of the disease. […] Evidence supporting this hypothesis includes loss of heterozygosity on the 17p chromosome. […] The p53 (a tumor suppressor gene in the normal population) genome on 17p in neurofibrosarcoma patients is mutated, increasing the probability of cancer. […] The normal p53 gene will regulate cell growth and inhibit any uncontrollable cell growth in the healthy population; since p53 is inactivated in neurofibrosarcoma patients, they are much more susceptible to developing tumors.

• #7 Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

  https://www.mdpi.com/2227-9067/9/1/38

  Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas (STS) with nerve sheath differentiation and a tendency to metastasize. […] Although occurring at an incidence of 0.001% in the general population, they are relatively common in individuals with neurofibromatosis type 1 (NF1), for whom the lifetime risk approaches 10%. […] Up to 50% of all MPNSTs occur in patients with NF1. […] MPNSTs may arise de novo from a peripheral nerve OR as a malignant transformation of a pre-existing benign nerve sheath tumor—especially neurofibromas. […] MPNSTs are the former, as their presence does not specifically define the presence of Neurofibromatosis type 1 (NF1), nor are they required for its diagnosis. […] Still, they are considered a hallmark of NF1 when present.

• #8 Malignant peripheral nerve sheath tumor causes – wikidoc

  https://www.wikidoc.org/index.php/Malignant_peripheral_nerve_sheath_tumor_causes

  Malignant peripheral nerve sheath tumor may be caused by a mutation in the neurofibromatosis type I gene. […] About half of the cases of malignant peripheral nerve sheath tumor (MPNST) occur along with NF1. The lifetime risk of having both of these conditions is at 813% while those with only MPNST have a 0.001% in the general population. […] The NF1 gene locus is on chromosome 17q11.2 and the gene product is neurofibromin, which acts as a tumor suppressor. Inactivation of the gene predisposes to tumor development.

• #9 Malignant peripheral nerve sheath tumor – Wikipedia

  https://en.wikipedia.org/wiki/Malignant_peripheral_nerve_sheath_tumor

  A malignant peripheral nerve sheath tumor (MPNST) is a form of cancer of the connective tissue surrounding peripheral nerves. […] About half the cases are diagnosed in people with neurofibromatosis; the lifetime risk for an MPNST in patients with neurofibromatosis type 1 is 813%. […] Soft tissue sarcomas have been linked within families, so it is hypothesized that neurofibrosarcoma may be genetic, although researchers still do not know the exact cause of the disease. […] Evidence supporting this hypothesis includes loss of heterozygosity on the 17p chromosome. […] The p53 (a tumor suppressor gene in the normal population) genome on 17p in neurofibrosarcoma patients is mutated, increasing the probability of cancer. […] The normal p53 gene will regulate cell growth and inhibit any uncontrollable cell growth in the healthy population; since p53 is inactivated in neurofibrosarcoma patients, they are much more susceptible to developing tumors.

• #10 Malignant peripheral nerve sheath tumours in inherited disease | Clinical Sarcoma Research | Full Text

  https://clinicalsarcomaresearch.biomedcentral.com/articles/10.1186/2045-3329-2-17

  Malignant peripheral nerve sheath tumours (MPNST) are rare tumours known to occur at high frequency in neurofibromatosis 1 (NF1), but may also occur in other cancer prone syndromes. […] MPNST is associated with schwannomatosis and TP53 mutations and is confirmed at high frequency in NF1. […] The presence of three confirmed TP53 mutation carriers with MPNST makes a link with germline TP53 mutations and Li Fraumeni syndrome very likely. […] In conclusion MPNST appears to occur at increased frequency in schwannomatosis and in those with germline TP53 mutations as well as those with NF1.

• #11 Malignant peripheral nerve sheath tumor | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/malignant-peripheral-nerve-sheath-tumour?lang=us

  Malignant peripheral nerve sheath tumors (MPNSTs) are forms of peripheral nerve sheath tumors occurring either de novo or arising from pre-existing tumors (e.g. neurofibromas, schwannomas etc.). Approximately half of such tumors are seen in individuals with neurofibromatosis type I (NF1), in such cases arising from pre-existing neurofibromas. […] Malignant peripheral nerve sheath tumors can arise in a number of different situations: de novo, de-differentiation, radiation therapy-associated. […] Most MPNSTs demonstrate inactivation of a number of genes: NF1, CDKN2A, and PRC2. […] It is worth noting that this grading is in contrast many benign neurogenic tumors (e.g. neurofibromas, schwannomas and perineuriomas) that sometimes can give rise to MPNST are given a grade of 1 in the WHO classification of CNS tumors.

• #12 Neural-crest Stem Cells and Malignant Peripheral Nerve Sheath Tumor (MPNST) | Zhu (Yuan) Lab | UT Southwestern, Dallas, Texas

  https://labs.utsouthwestern.edu/zhu-yuan-lab/research/neural-crest-stem-cells-and-malignant-peripheral-nerve-sheath-tumor-mpnst

  MPNST, a sarcoma arising from the neural-crest stem cell lineage in the peripheral nerve, is the leading cause of death for individuals with NF1. […] Inactivation of NF1 drives benign PNF formation by abnormal activation of the RAS-mediated MEK-ERK/MAPK signaling pathway. […] However, premalignant ANFs carry additional genetic alterations at the CDKN2A locus, which encodes two tumor suppressor genes, p16INK4A and p14ARF (p19Arf in mice). […] Thus, the CDKN2A/ARF-MDM2-p53 regulatory axis is the major tumor suppressive pathway(s) that inhibits the malignant transformation of benign PNFs. […] In addition to the loss of NF1 and CDKN2A, more than half of MPNSTs also harbor additional oncogenic driver mutations, in components of the POLYCOMB REPRESSIVE COMPLEX 2 (PRC2), most frequently SUZ12 or EED.

• #13 Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma | eLife

  https://elifesciences.org/articles/74238

  Malignant peripheral nerve sheath tumors (MPNST) are the deadliest cancer that arises in individuals diagnosed with neurofibromatosis and account for nearly 5% of the 15,000 soft tissue sarcomas diagnosed in the United States each year. […] Primary risk factors for developing MPNST include existing plexiform neurofibromas (PN), prior radiotherapy treatment, and expansive germline mutations involving the entire NF1 gene and surrounding genes. […] Bi-allelic loss of NF1 is not sufficient for malignant transformation of PN to MPNST. […] Additional mutations or copy number alterations of genes such as TP53, SUZ12, EGFR, CDKN2A, and TERT that are often not present in benign PN suggest that these alterations represent advanced progression to atypical neurofibroma (AN) and MPNST. […] Liquid biopsies that assay for mutations or aneuploidy in circulating tumor DNA (ctDNA) represent an attractive, minimally invasive option that could be performed at each longitudinal patient visit. […] Mutations in polycomb repressive complex 2 (PRC2) subunits such as SUZ12 and EED are found in nearly 70% of MPNST. […] Malignant transformation of a plexiform neurofibroma to MPSNT can occur over years.

• #14 Neural-crest Stem Cells and Malignant Peripheral Nerve Sheath Tumor (MPNST) | Zhu (Yuan) Lab | UT Southwestern, Dallas, Texas

  https://labs.utsouthwestern.edu/zhu-yuan-lab/research/neural-crest-stem-cells-and-malignant-peripheral-nerve-sheath-tumor-mpnst

  MPNST, a sarcoma arising from the neural-crest stem cell lineage in the peripheral nerve, is the leading cause of death for individuals with NF1. […] Inactivation of NF1 drives benign PNF formation by abnormal activation of the RAS-mediated MEK-ERK/MAPK signaling pathway. […] However, premalignant ANFs carry additional genetic alterations at the CDKN2A locus, which encodes two tumor suppressor genes, p16INK4A and p14ARF (p19Arf in mice). […] Thus, the CDKN2A/ARF-MDM2-p53 regulatory axis is the major tumor suppressive pathway(s) that inhibits the malignant transformation of benign PNFs. […] In addition to the loss of NF1 and CDKN2A, more than half of MPNSTs also harbor additional oncogenic driver mutations, in components of the POLYCOMB REPRESSIVE COMPLEX 2 (PRC2), most frequently SUZ12 or EED.

• #15 Malignant Peripheral Nerve Sheath Tumors

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3926794/

  The large number of molecular aberrations associated with MPNST in both preclinical and clinical studies across a variety of platforms is, on the other hand, not in doubt; MPNST is a genomically complex disease. […] Although relatively similar molecular mechanisms are involved in the pathogenesis of sporadic MPNST, which comprise approximately 40% of all MPNST, there are some distinct differences between these tumors and the NF1-associated variety. […] The remaining 10% of MPNSTs arise secondary to previous irradiation and account for about 5% of radiotherapy (RT)-induced sarcomas, which arise most frequently in the setting of external beam RT for breast cancer or lymphoma. […] The true prognostic impact of NF1 syndrome in MPNST remains somewhat in flux. Several large series report significantly worse outcomes for MPNST arising in the setting of NF1 compared with sporadic disease, with inferior responses to cytotoxic chemotherapy and 5-year survivals that are up to 50% worse. […] The complexity of ras signaling is an obvious target but has proved a nettlesome signaling pathway to target to date, although downstream elements such as MEK may be more easily inhibited.

• #16

  https://link.springer.com/article/10.1007/s11523-024-01078-5

  Malignant peripheral sheath tumor (MPNST) is a rare, aggressive form of soft-tissue sarcoma that presents a unique set of diagnostic and treatment challenges and is associated with major unmet treatment medical needs. […] MPNST has an incidence of 1:100,000 in the general population and 1:3500 among patients with the inherited condition of neurofibromatosis-1. […] Highly copy-number aberrant and enriched in chromosome 8, MPNSTs have a complex molecular pathogenesis that likely involves the interplay of multiple signaling pathways, including Ras/AKT/mTOR/MAPK, EGFR, p53, PTEN, and PRC2, as well as factors in the tumor microenvironment. […] Despite advances in our understanding of the genetics and molecular biology of MPNST, further research is warranted to: (1) unravel the complex pathogenesis of this condition; (2) improve diagnostic yield; (3) delineate the appropriate roles of chemotherapy and radiation; and (4) develop a targeted therapy (or combination of such treatments) that is well tolerated and prolongs survival.

• #17 Malignant Peripheral Nerve Sheath Tumors

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3926794/

  Malignant peripheral nerve sheath tumors are amongst the most challenging mesenchymal malignancies to treat. Their frequent association with a seemingly simple genetic aberrationthe loss of the tumor suppressor gene neurofibrominbelies genomic complexity that has rendered effective therapy elusive to date. […] Half of MPNSTs are associated with neurofibromatosis type 1 (NF1), the autosomal dominant condition that, affecting 1 in 3000 live births, represents the most common human cancer genetic predisposition syndrome. […] The genotypic hallmark of NF1 involves mutations to or other loss of the 350 kilobase gene NF1 on the long arm of chromosome 17, which encodes the tumor suppressor protein neurofibromin. […] The subsequent molecular path from neurofibroma to MPNST in NF1 syndrome remains uncertain, although NF1 deficiency in and of itself is clearly insufficient, given that only approximately 10% of all NF1 patients eventually develop MPNST.

• #18 Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8774267/

  Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas (STS) with nerve sheath differentiation and a tendency to metastasize. Although occurring at an incidence of 0.001% in the general population, they are relatively common in individuals with neurofibromatosis type 1 (NF1), for whom the lifetime risk approaches 10%. […] MPNSTs may arise de novo from a peripheral nerve OR as a malignant transformation of a pre-existing benign nerve sheath tumor especially neurofibromas. […] MPNSTs are most often characterized by the second variety of mutations specifically by loss of function of the tumor suppressor gene NF1. […] Although bi-allelic NF1 inactivation or mutation appears necessary for MPNST development, it does not seem sufficient. […] Therefore, one potential model for MPNST development proposes that bi-allelic NF1 loss occurs in nerve-sheath precursor cells, resulting in benign neurofibroma formation.

• #19 Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8774267/

  Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas (STS) with nerve sheath differentiation and a tendency to metastasize. Although occurring at an incidence of 0.001% in the general population, they are relatively common in individuals with neurofibromatosis type 1 (NF1), for whom the lifetime risk approaches 10%. […] MPNSTs may arise de novo from a peripheral nerve OR as a malignant transformation of a pre-existing benign nerve sheath tumor especially neurofibromas. […] MPNSTs are most often characterized by the second variety of mutations specifically by loss of function of the tumor suppressor gene NF1. […] Although bi-allelic NF1 inactivation or mutation appears necessary for MPNST development, it does not seem sufficient. […] Therefore, one potential model for MPNST development proposes that bi-allelic NF1 loss occurs in nerve-sheath precursor cells, resulting in benign neurofibroma formation.

• #20 Malignant Peripheral Nerve Sheath Tumor – NCI

  https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-soft-tissue-tumors/mpnst

  MPNST is more common in people with a genetic condition called neurofibromatosis type 1 (NF1). About 25% to 50% of people with MPNST have NF1. […] MPNST forms when the sheath cells that cover nerves grow and divide more than normal. The fact that almost half of MPNSTs occur in people with neurofibromatosis type 1 may give scientists some clues. Scientists are always working to understand how cancer forms, but it can be hard to prove.

• #21 Malignant Peripheral Nerve Sheath Tumor (MPNST)

  https://my.clevelandclinic.org/health/diseases/malignant-peripheral-nerve-sheath-tumor-mpnst

  Malignant peripheral nerve sheath tumors (MPNSTs) affect nerves that manage your muscles and sense of touch. In MPNST, cells that make up nerves protective shield become cancerous and multiply to develop tumors. Its a very rare cancer that grows very quickly. […] People who have the inherited disorder neurofibromatosis type 1 (NF1) often develop MPNST. Between 25% and 50% of people who have a malignant peripheral nerve sheath tumor also have NF1. […] Studies show neurofibromatosis type 1 accounts for 50% of malignant peripheral nerve sheath tumors. Other causes include: […] Genetic mutations: Researchers have found several different genetic mutations that turn normal nerve sheath cells into abnormal cells that multiply and create tumors. […] Certain neurofibromas: People with plexiform neurofibroma have an increased risk for MPNST.

• #22 Pathology Outlines – Malignant peripheral nerve sheath tumor (MPNST)

  https://www.pathologyoutlines.com/topic/softtissuempnst.html

  Malignant neoplasm arising from peripheral nerve […] May arise from a preexisting nerve sheath tumor in neurofibromatosis type 1 (NF1) or in the setting of prior radiation therapy […] In the absence of association with NF1 or radiation, diagnosis is challenging and based on histologic and immunohistochemical features suggesting Schwannian differentiation […] MPNST can occur in the following settings: Sporadic (approximately 50%) […] In neurofibromatosis type 1 (40 – 50%) […] In the setting of prior radiation therapy (10%) […] Germline mutations in NF1 predispose to the development of peripheral nerve sheath neoplasms in patients with type 1 neurofibromatosis […] In the setting of NF1, lesions often arise from plexiform neurofibroma […] Radiation therapy predisposes to the development of secondary sarcomas through repeated DNA damage and defective repair

• #23

  https://www.advocatehealth.com/health-services/brain-spine-institute/peripheral-nerve-tumors/malignant-peripheral-nerve-sheath-tumor

  Malignant peripheral nerve sheath tumors are exceedingly rare. […] We dont know what causes malignant peripheral nerve sheath tumors. Recent research has discovered links to genes in these cancers that may lead to more effective therapies. […] People who have a genetic condition called neurofibromatosis type 1 make up about 50% of those diagnosed with a malignant peripheral nerve sheath tumor. Having had previous exposure to radiation, either environmental or through radiation treatment, is another risk factor. […] Some malignant peripheral nerve sheath tumors happen randomly without any known risk factors.

• #24 Malignant peripheral nerve sheath tumor – Wikipedia

  https://en.wikipedia.org/wiki/Malignant_peripheral_nerve_sheath_tumor

  About half of these cases also happen to occur along with neurofibromatosis type 1 (NF-1), which is a genetic mutation on the 17th chromosome which causes tumors along the nervous system. […] The lifetime risk of patients with NF-1 developing MPNST has been estimated at 813%, while those with only MPNST have a 0.001% in the general population. […] NF-1 and MPNST are categorized as autosomal dominant disorders.

• #25 Nerve Sheath Tumors: Types, Symptoms, Treatment, Outlook

  https://www.healthline.com/health/nerve-sheath-tumor

  Nerve sheath tumors are rare tumors that grow on the lining of nerve cells. […] Nerve sheath tumors are usually noncancerous (benign) but can sometimes be cancerous (malignant). […] Malignant tumors often require surgery and sometimes chemotherapy and radiation. […] Neurofibromas also include a more aggressive subtype known as a malignant peripheral nerve sheath tumor (MPNST). […] Although rare, malignant nerve sheath tumors grow and spread rapidly and require more aggressive treatment. […] Nerve sheath tumors occur due to mutations (changes) in your genes that result in the overactivation of nerve sheath cells. […] Researchers arent sure what causes these mutations to occur. […] The risk of a malignant nerve sheath tumor is higher in people with NF1. […] According to the National Cancer Institute (NCI), about 8% to 13% of people with NF1 will get MPNST in their lifetime. […] MPNST can grow and spread quickly. […] According to the NCI, between 23% and 69% of people with MPNST survive for at least 5 years after diagnosis. […] In rare cases, nerve sheath tumors can become cancerous and may require aggressive treatment.

• #26 Malignant Peripheral Nerve Sheath Tumor (MPNST)

  https://my.clevelandclinic.org/health/diseases/malignant-peripheral-nerve-sheath-tumor-mpnst

  Malignant peripheral nerve sheath tumors (MPNSTs) affect nerves that manage your muscles and sense of touch. In MPNST, cells that make up nerves protective shield become cancerous and multiply to develop tumors. Its a very rare cancer that grows very quickly. […] People who have the inherited disorder neurofibromatosis type 1 (NF1) often develop MPNST. Between 25% and 50% of people who have a malignant peripheral nerve sheath tumor also have NF1. […] Studies show neurofibromatosis type 1 accounts for 50% of malignant peripheral nerve sheath tumors. Other causes include: […] Genetic mutations: Researchers have found several different genetic mutations that turn normal nerve sheath cells into abnormal cells that multiply and create tumors. […] Certain neurofibromas: People with plexiform neurofibroma have an increased risk for MPNST.

• #27 Malignant Peripheral Nerve Sheath Tumors: Latest Concepts in Disease Pathogenesis and Clinical Management

  https://www.mdpi.com/2072-6694/15/4/1077

  Several studies over the last decade have indicated that NF1-associated MPNSTs typically begin as plexiform neurofibroma (PN) and atypical neurofibromatous neoplasm of unknown biological potential (ANNUBP). […] The probability of malignant progression to MPNST is 10–15%. […] In summary, previous studies have found numerous risk factors associated with the onset of MPNST. NF1 is the most important factor in 50% of MPNST patients. The history of therapeutic irradiation can also increase the risk of MPSNT. Possession of PN and ANNUBP has malignant potential to cause MPNST development. Additionally, aging is an important risk factor because MPNST development takes a long time.

• #28 Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8774267/

  Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas (STS) with nerve sheath differentiation and a tendency to metastasize. Although occurring at an incidence of 0.001% in the general population, they are relatively common in individuals with neurofibromatosis type 1 (NF1), for whom the lifetime risk approaches 10%. […] MPNSTs may arise de novo from a peripheral nerve OR as a malignant transformation of a pre-existing benign nerve sheath tumor especially neurofibromas. […] MPNSTs are most often characterized by the second variety of mutations specifically by loss of function of the tumor suppressor gene NF1. […] Although bi-allelic NF1 inactivation or mutation appears necessary for MPNST development, it does not seem sufficient. […] Therefore, one potential model for MPNST development proposes that bi-allelic NF1 loss occurs in nerve-sheath precursor cells, resulting in benign neurofibroma formation.

• #29 Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

  https://www.mdpi.com/2227-9067/9/1/38

  Although bi-allelic NF1 inactivation or mutation appears necessary for MPNST development, it does not seem sufficient. […] Therefore, one potential model for MPNST development proposes that bi-allelic NF1 loss occurs in nerve-sheath precursor cells, resulting in benign neurofibroma formation. […] Patients with NF1 possess only a single functional copy of the NF1 gene (e.g., the “first hit”), with loss of the second copy acting as an oncogenic “second hit” and thereby allowing constitutive activation of this pathway. […] A particular characteristic of NF1 is the extreme heterogeneity of its clinical manifestations, which may vary wildly even among members of the same kindred. […] Although many MPNSTs are therefore sporadic, a diagnosis of NF1 is the primary known risk factor. […] Moreover, among those patients with NF1, a family history of NF1 and MPNST appears to be associated with an approximately three-fold greater risk of developing an MPNST in that patient.

• #30

  https://link.springer.com/article/10.1007/s11523-024-01078-5

  A history of radiation exposure is present in approximately 10-13% of MPNST cases, with a typical latency period exceeding 16 years. […] NF1-associated plexiform neurofibromas have an approximately 10% risk of malignant transformation, with a higher overall risk in more centrally located neoplasms of the torso and proximal limbs as well as large nerve trunks. […] Loss of NF1 gene expression is considered a necessary but not sufficient condition for MPNST development; other cooperating genetic (and epigenetic) events are required. […] A complex network of signaling pathways underlies the oncogenesis and progression of MPNST. These diverse pathways may open avenues for the development of targeted pharmacotherapies. […] AXL is a receptor tyrosine kinase associated with the survival, growth, and metastasis of MPNST cells.

• #31 Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8774267/

  The other primary known risk factor for MPNST development is radiation exposure, typically in the context of a secondary malignant neoplasm occurring following radiotherapy. […] In most series, patients with either a diagnosis of NF1 or prior radiotherapy have shown a worse overall survival compared to those with sporadic MPNSTs likely due to the greater propensity towards metastases and/or local invasion demonstrated by tumors in these patients. […] However, the presence of NF1 itself does not directly appear to be the causative risk factor for these poorer outcomes instead, patients with NF1 tend to have larger tumors, which are more challenging to fully resect. […] A particular characteristic of NF1 is the extreme heterogeneity of its clinical manifestations, which may vary wildly even among members of the same kindred. […] Although many MPNSTs are therefore sporadic, a diagnosis of NF1 is the primary known risk factor.

• #32 Malignant Peripheral Nerve Sheath Tumors

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3926794/

  The large number of molecular aberrations associated with MPNST in both preclinical and clinical studies across a variety of platforms is, on the other hand, not in doubt; MPNST is a genomically complex disease. […] Although relatively similar molecular mechanisms are involved in the pathogenesis of sporadic MPNST, which comprise approximately 40% of all MPNST, there are some distinct differences between these tumors and the NF1-associated variety. […] The remaining 10% of MPNSTs arise secondary to previous irradiation and account for about 5% of radiotherapy (RT)-induced sarcomas, which arise most frequently in the setting of external beam RT for breast cancer or lymphoma. […] The true prognostic impact of NF1 syndrome in MPNST remains somewhat in flux. Several large series report significantly worse outcomes for MPNST arising in the setting of NF1 compared with sporadic disease, with inferior responses to cytotoxic chemotherapy and 5-year survivals that are up to 50% worse. […] The complexity of ras signaling is an obvious target but has proved a nettlesome signaling pathway to target to date, although downstream elements such as MEK may be more easily inhibited.

• #33 Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

  https://www.mdpi.com/2227-9067/9/1/38

  The other primary known risk factor for MPNST development is radiation exposure, typically in the context of a secondary malignant neoplasm occurring following radiotherapy. […] In most series, patients with either a diagnosis of NF1 or prior radiotherapy have shown a worse overall survival compared to those with sporadic MPNSTs—likely due to the greater propensity towards metastases and/or local invasion demonstrated by tumors in these patients.

• #34

  https://link.springer.com/article/10.1007/s11523-024-01078-5

  A history of radiation exposure is present in approximately 10-13% of MPNST cases, with a typical latency period exceeding 16 years. […] NF1-associated plexiform neurofibromas have an approximately 10% risk of malignant transformation, with a higher overall risk in more centrally located neoplasms of the torso and proximal limbs as well as large nerve trunks. […] Loss of NF1 gene expression is considered a necessary but not sufficient condition for MPNST development; other cooperating genetic (and epigenetic) events are required. […] A complex network of signaling pathways underlies the oncogenesis and progression of MPNST. These diverse pathways may open avenues for the development of targeted pharmacotherapies. […] AXL is a receptor tyrosine kinase associated with the survival, growth, and metastasis of MPNST cells.

• #35 Diagnosis, Treatment and Survival of 65 Patients with Malignant Peripheral Nerve Sheath Tumors | Anticancer Research

  https://ar.iiarjournals.org/content/34/2/777

  Malignant peripheral nerve sheath tumors (MPNST) account for up to 10% of all malignant soft tissue tumors in adults. […] The most important known risk factor for MPNST is neurofibromatosis 1 (NF1); up to 29% of patients with NF1 suffer from MPNST in the course of their life; 50-60% of MPNSTs occur in patients with NF1. […] The second known factor causing MPNST is radiation exposure 4-41 years prior to tumor occurrence, found for 10% of patients with MPNST. […] The diagnosis should begin with a complete medical and family history and a physical examination, focusing on the skin and neurology. […] The most important known risk factor for MPNST development is NF1, in which 10% of patients develop an MPNST during their lifetime. […] The second known risk factor for developing an MPNST is radiation exposure decades prior to occurrence of MPNST, recorded for 10% of patients.

• #36 Pathology Outlines – Malignant peripheral nerve sheath tumor (MPNST)

  https://www.pathologyoutlines.com/topic/softtissuempnst.html

  Malignant neoplasm arising from peripheral nerve […] May arise from a preexisting nerve sheath tumor in neurofibromatosis type 1 (NF1) or in the setting of prior radiation therapy […] In the absence of association with NF1 or radiation, diagnosis is challenging and based on histologic and immunohistochemical features suggesting Schwannian differentiation […] MPNST can occur in the following settings: Sporadic (approximately 50%) […] In neurofibromatosis type 1 (40 – 50%) […] In the setting of prior radiation therapy (10%) […] Germline mutations in NF1 predispose to the development of peripheral nerve sheath neoplasms in patients with type 1 neurofibromatosis […] In the setting of NF1, lesions often arise from plexiform neurofibroma […] Radiation therapy predisposes to the development of secondary sarcomas through repeated DNA damage and defective repair

• #37 Malignant Peripheral Nerve Sheath Tumors

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3926794/

  The large number of molecular aberrations associated with MPNST in both preclinical and clinical studies across a variety of platforms is, on the other hand, not in doubt; MPNST is a genomically complex disease. […] Although relatively similar molecular mechanisms are involved in the pathogenesis of sporadic MPNST, which comprise approximately 40% of all MPNST, there are some distinct differences between these tumors and the NF1-associated variety. […] The remaining 10% of MPNSTs arise secondary to previous irradiation and account for about 5% of radiotherapy (RT)-induced sarcomas, which arise most frequently in the setting of external beam RT for breast cancer or lymphoma. […] The true prognostic impact of NF1 syndrome in MPNST remains somewhat in flux. Several large series report significantly worse outcomes for MPNST arising in the setting of NF1 compared with sporadic disease, with inferior responses to cytotoxic chemotherapy and 5-year survivals that are up to 50% worse. […] The complexity of ras signaling is an obvious target but has proved a nettlesome signaling pathway to target to date, although downstream elements such as MEK may be more easily inhibited.

• #38 Malignant peripheral nerve sheath tumors | Altru Health System

  https://www.altru.org/health-library/conditions/malignant-peripheral-nerve-sheath-tumors

  Malignant peripheral nerve sheath tumors are rare cancers that start in the lining of the nerves. […] It’s not clear what causes most malignant peripheral nerve sheath tumors. […] Experts know that these cancers begin when a cell in the lining around a nerve gets changes in its DNA. […] The changes tell the cells to make more cells quickly. […] These cells continue to live when healthy cells die as part of their life cycle. […] The cells then can form a mass called a tumor. […] Factors that increase the risk of malignant peripheral nerve sheath tumors include: […] A malignant peripheral nerve sheath tumor might occur in the area treated with radiation 10 to 20 years after treatment. […] Malignant peripheral nerve sheath tumors can develop from nerve tumors that aren’t cancerous, such as neurofibroma. […] Malignant peripheral nerve sheath tumors occur more often in people with neurofibromatosis 1.

• #39 Malignant peripheral nerve sheath tumors

  https://www.mymlc.com/health-information/diseases-and-conditions/m/malignant-peripheral-nerve-sheath-tumors/?section=Risk%20factors

  Malignant peripheral nerve sheath tumors are a rare type of cancer that occurs in the lining of the nerves that extend from the spinal cord into the body. […] It’s not clear what causes most malignant peripheral nerve sheath tumors. […] Doctors know that these cancers begin when a cell in the protective lining around a nerve develops an error (mutation) in its DNA. The mutation tells the cell to multiply rapidly and to continue living when other cells would normally die. The accumulating cells form a tumor that can grow to invade nearby tissue or spread to other areas of the body. […] Factors that increase the risk of malignant peripheral nerve sheath tumors include: Previous radiation therapy for cancer. A malignant peripheral nerve sheath tumor may develop in the area treated with radiation 10 to 20 years after treatment. Noncancerous nerve tumors. Malignant peripheral nerve sheath tumors can develop from noncancerous (benign) nerve tumors, such as neurofibroma. An inherited condition that increases risk of nerve tumors. Malignant peripheral nerve sheath tumors occur more frequently in people with neurofibromatosis 1.

• #40 A Rare Case of Malignant Peripheral Nerve Sheath Tumor in Neck and Role of VMAT Radiotherapy

  https://www.ijhns.com/abstractArticleContentBrowse/IJHNS/31747/JPJ/fullText

  Malignant peripheral nerve sheath tumor (MPNST) is a rare and aggressive variety of sarcoma. It usually arises from peripheral nerves or cells of the peripheral nerve sheath, like Schwann cells, perineural fibroblast, or endoneurial fibroblast. It constitutes 510% of soft tissue sarcomas, of which, only 816% are found in the head and neck region. They are usually found in patients with NF-1, but also can arise sporadically. They have a high rate of local recurrence and rapid disease progression leading to very poor prognosis despite aggressive therapy and complete resection. […] The mitogen-activated protein kinase (MAPK) pathway, phosphatidylinositol 3-kinases/mouse strain activated kinase (AK) thymoma/(mechanistic) target of rapamycin (PI3K/AKT/mTOR) pathway, and TP53 mutation are some of the major contributors of development of MPNST. About 10% of MPNST arise due to previous irradiation, most commonly associated with irradiation of breast cancer and lymphoma. Such MPNSTs have a poorer prognosis.

• #41 A Rare Case of Malignant Peripheral Nerve Sheath Tumor in Neck and Role of VMAT Radiotherapy

  https://www.ijhns.com/abstractArticleContentBrowse/IJHNS/31747/JPJ/fullText

  Malignant peripheral nerve sheath tumor (MPNST) is a rare and aggressive variety of sarcoma. It usually arises from peripheral nerves or cells of the peripheral nerve sheath, like Schwann cells, perineural fibroblast, or endoneurial fibroblast. It constitutes 510% of soft tissue sarcomas, of which, only 816% are found in the head and neck region. They are usually found in patients with NF-1, but also can arise sporadically. They have a high rate of local recurrence and rapid disease progression leading to very poor prognosis despite aggressive therapy and complete resection. […] The mitogen-activated protein kinase (MAPK) pathway, phosphatidylinositol 3-kinases/mouse strain activated kinase (AK) thymoma/(mechanistic) target of rapamycin (PI3K/AKT/mTOR) pathway, and TP53 mutation are some of the major contributors of development of MPNST. About 10% of MPNST arise due to previous irradiation, most commonly associated with irradiation of breast cancer and lymphoma. Such MPNSTs have a poorer prognosis.

• #42 Pathology Outlines – Malignant peripheral nerve sheath tumor (MPNST)

  https://www.pathologyoutlines.com/topic/softtissuempnst.html

  Malignant neoplasm arising from peripheral nerve […] May arise from a preexisting nerve sheath tumor in neurofibromatosis type 1 (NF1) or in the setting of prior radiation therapy […] In the absence of association with NF1 or radiation, diagnosis is challenging and based on histologic and immunohistochemical features suggesting Schwannian differentiation […] MPNST can occur in the following settings: Sporadic (approximately 50%) […] In neurofibromatosis type 1 (40 – 50%) […] In the setting of prior radiation therapy (10%) […] Germline mutations in NF1 predispose to the development of peripheral nerve sheath neoplasms in patients with type 1 neurofibromatosis […] In the setting of NF1, lesions often arise from plexiform neurofibroma […] Radiation therapy predisposes to the development of secondary sarcomas through repeated DNA damage and defective repair

• #43 Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8774267/

  Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas (STS) with nerve sheath differentiation and a tendency to metastasize. Although occurring at an incidence of 0.001% in the general population, they are relatively common in individuals with neurofibromatosis type 1 (NF1), for whom the lifetime risk approaches 10%. […] MPNSTs may arise de novo from a peripheral nerve OR as a malignant transformation of a pre-existing benign nerve sheath tumor especially neurofibromas. […] MPNSTs are most often characterized by the second variety of mutations specifically by loss of function of the tumor suppressor gene NF1. […] Although bi-allelic NF1 inactivation or mutation appears necessary for MPNST development, it does not seem sufficient. […] Therefore, one potential model for MPNST development proposes that bi-allelic NF1 loss occurs in nerve-sheath precursor cells, resulting in benign neurofibroma formation.

• #44 Malignant peripheral nerve sheath tumor | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/malignant-peripheral-nerve-sheath-tumour?lang=us

  Malignant peripheral nerve sheath tumors (MPNSTs) are forms of peripheral nerve sheath tumors occurring either de novo or arising from pre-existing tumors (e.g. neurofibromas, schwannomas etc.). Approximately half of such tumors are seen in individuals with neurofibromatosis type I (NF1), in such cases arising from pre-existing neurofibromas. […] Malignant peripheral nerve sheath tumors can arise in a number of different situations: de novo, de-differentiation, radiation therapy-associated. […] Most MPNSTs demonstrate inactivation of a number of genes: NF1, CDKN2A, and PRC2. […] It is worth noting that this grading is in contrast many benign neurogenic tumors (e.g. neurofibromas, schwannomas and perineuriomas) that sometimes can give rise to MPNST are given a grade of 1 in the WHO classification of CNS tumors.

• #45 Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

  https://www.mdpi.com/2227-9067/9/1/38

  Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas (STS) with nerve sheath differentiation and a tendency to metastasize. […] Although occurring at an incidence of 0.001% in the general population, they are relatively common in individuals with neurofibromatosis type 1 (NF1), for whom the lifetime risk approaches 10%. […] Up to 50% of all MPNSTs occur in patients with NF1. […] MPNSTs may arise de novo from a peripheral nerve OR as a malignant transformation of a pre-existing benign nerve sheath tumor—especially neurofibromas. […] MPNSTs are the former, as their presence does not specifically define the presence of Neurofibromatosis type 1 (NF1), nor are they required for its diagnosis. […] Still, they are considered a hallmark of NF1 when present.

• #46 Malignant Peripheral Nerve Sheath Tumors: Differentiation Patterns and Immunohistochemical Features – A Mini-Review and Our New Findings

  https://www.jcancer.org/v03p0303.htm

  Malignant peripheral nerve sheath tumors (MPNST) represent a group of highly heterogeneous human malignancies often with multiple histological origins, divergent differentiation patterns, and diverse immunohistochemical presentations. […] Malignant peripheral nerve sheath tumor (MPNST), also known as Malignant schwannoma, Neurofibrosarcoma, or Neurosarcoma, is derived from Schwann cells or pluripotent cells of the neural crest. […] One half to two thirds arises from neurofibromas, often of plexiform neurofibromas or in the setting of neurofibromatosis type I, which occur frequently on the head or neck. The other MPNSTs arise de novo, which usually involve the peripheral nerves in the buttocks or thighs, mostly the sciatic nerve. […] MPNST is a tumor associated with an aggressive behavior and its prognosis is poor with death occurring in 63%, usually with 2-year of diagnosis.

• #47 Malignant Peripheral Nerve Sheath Tumors: Latest Concepts in Disease Pathogenesis and Clinical Management

  https://www.mdpi.com/2072-6694/15/4/1077

  Several studies over the last decade have indicated that NF1-associated MPNSTs typically begin as plexiform neurofibroma (PN) and atypical neurofibromatous neoplasm of unknown biological potential (ANNUBP). […] The probability of malignant progression to MPNST is 10–15%. […] In summary, previous studies have found numerous risk factors associated with the onset of MPNST. NF1 is the most important factor in 50% of MPNST patients. The history of therapeutic irradiation can also increase the risk of MPSNT. Possession of PN and ANNUBP has malignant potential to cause MPNST development. Additionally, aging is an important risk factor because MPNST development takes a long time.

• #48 Malignant Peripheral Nerve Sheath Tumors – Rein in Sarcoma

  https://www.reininsarcoma.org/mpnst/

  Malignant schwannoma, also known as a malignant peripheral nerve sheath tumor (MPNST), is a type of soft tissue sarcoma that originates in the lining (sheath) of peripheral nerves that emerge from the spinal cord. […] Studies suggest that MPNSTs do not demonstrate a gender predilection and can arise at any age. However, the etiology of the tumor can influence the age of presentation. For example, about 50% of the time, MPNSTs are associated with a genetic syndrome called neurofibromatosis type 1 (NF1). […] Half of all malignant peripheral nerve sheath tumors develop secondary to neurofibromatosis type 1, a genetic syndrome caused by an autosomal dominant loss of function mutation in the tumor suppressor gene neurofibromin. […] Neurofibromas are not always associated with NF1. In fact, a majority of the time, they are sporadic tumors. Therefore, MPNSTs do not always arise due to an inherited condition; they can also develop from a stand-alone, benign neurofibroma.

• #49 Malignant Peripheral Nerve Sheath Tumors: Latest Concepts in Disease Pathogenesis and Clinical Management

  https://www.mdpi.com/2072-6694/15/4/1077

  Several studies over the last decade have indicated that NF1-associated MPNSTs typically begin as plexiform neurofibroma (PN) and atypical neurofibromatous neoplasm of unknown biological potential (ANNUBP). […] The probability of malignant progression to MPNST is 10–15%. […] In summary, previous studies have found numerous risk factors associated with the onset of MPNST. NF1 is the most important factor in 50% of MPNST patients. The history of therapeutic irradiation can also increase the risk of MPSNT. Possession of PN and ANNUBP has malignant potential to cause MPNST development. Additionally, aging is an important risk factor because MPNST development takes a long time.

• #50 Pathology Outlines – Malignant peripheral nerve sheath tumor (MPNST)

  https://www.pathologyoutlines.com/topic/softtissuempnst.html

  Malignant neoplasm arising from peripheral nerve […] May arise from a preexisting nerve sheath tumor in neurofibromatosis type 1 (NF1) or in the setting of prior radiation therapy […] In the absence of association with NF1 or radiation, diagnosis is challenging and based on histologic and immunohistochemical features suggesting Schwannian differentiation […] MPNST can occur in the following settings: Sporadic (approximately 50%) […] In neurofibromatosis type 1 (40 – 50%) […] In the setting of prior radiation therapy (10%) […] Germline mutations in NF1 predispose to the development of peripheral nerve sheath neoplasms in patients with type 1 neurofibromatosis […] In the setting of NF1, lesions often arise from plexiform neurofibroma […] Radiation therapy predisposes to the development of secondary sarcomas through repeated DNA damage and defective repair

• #51 Malignant peripheral nerve sheath tumor | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/malignant-peripheral-nerve-sheath-tumour?lang=us

  Malignant peripheral nerve sheath tumors (MPNSTs) are forms of peripheral nerve sheath tumors occurring either de novo or arising from pre-existing tumors (e.g. neurofibromas, schwannomas etc.). Approximately half of such tumors are seen in individuals with neurofibromatosis type I (NF1), in such cases arising from pre-existing neurofibromas. […] Malignant peripheral nerve sheath tumors can arise in a number of different situations: de novo, de-differentiation, radiation therapy-associated. […] Most MPNSTs demonstrate inactivation of a number of genes: NF1, CDKN2A, and PRC2. […] It is worth noting that this grading is in contrast many benign neurogenic tumors (e.g. neurofibromas, schwannomas and perineuriomas) that sometimes can give rise to MPNST are given a grade of 1 in the WHO classification of CNS tumors.

• #52 Malignant Peripheral Nerve Sheath Tumors: Latest Concepts in Disease Pathogenesis and Clinical Management

  https://www.mdpi.com/2072-6694/15/4/1077

  Several studies over the last decade have indicated that NF1-associated MPNSTs typically begin as plexiform neurofibroma (PN) and atypical neurofibromatous neoplasm of unknown biological potential (ANNUBP). […] The probability of malignant progression to MPNST is 10–15%. […] In summary, previous studies have found numerous risk factors associated with the onset of MPNST. NF1 is the most important factor in 50% of MPNST patients. The history of therapeutic irradiation can also increase the risk of MPSNT. Possession of PN and ANNUBP has malignant potential to cause MPNST development. Additionally, aging is an important risk factor because MPNST development takes a long time.

• #53

  https://link.springer.com/article/10.1007/s11523-024-01078-5

  A history of radiation exposure is present in approximately 10-13% of MPNST cases, with a typical latency period exceeding 16 years. […] NF1-associated plexiform neurofibromas have an approximately 10% risk of malignant transformation, with a higher overall risk in more centrally located neoplasms of the torso and proximal limbs as well as large nerve trunks. […] Loss of NF1 gene expression is considered a necessary but not sufficient condition for MPNST development; other cooperating genetic (and epigenetic) events are required. […] A complex network of signaling pathways underlies the oncogenesis and progression of MPNST. These diverse pathways may open avenues for the development of targeted pharmacotherapies. […] AXL is a receptor tyrosine kinase associated with the survival, growth, and metastasis of MPNST cells.

• #54

  https://link.springer.com/article/10.1007/s11523-024-01078-5

  Malignant peripheral sheath tumor (MPNST) is a rare, aggressive form of soft-tissue sarcoma that presents a unique set of diagnostic and treatment challenges and is associated with major unmet treatment medical needs. […] MPNST has an incidence of 1:100,000 in the general population and 1:3500 among patients with the inherited condition of neurofibromatosis-1. […] Highly copy-number aberrant and enriched in chromosome 8, MPNSTs have a complex molecular pathogenesis that likely involves the interplay of multiple signaling pathways, including Ras/AKT/mTOR/MAPK, EGFR, p53, PTEN, and PRC2, as well as factors in the tumor microenvironment. […] Despite advances in our understanding of the genetics and molecular biology of MPNST, further research is warranted to: (1) unravel the complex pathogenesis of this condition; (2) improve diagnostic yield; (3) delineate the appropriate roles of chemotherapy and radiation; and (4) develop a targeted therapy (or combination of such treatments) that is well tolerated and prolongs survival.

• #55 Neural-crest Stem Cells and Malignant Peripheral Nerve Sheath Tumor (MPNST) | Zhu (Yuan) Lab | UT Southwestern, Dallas, Texas

  https://labs.utsouthwestern.edu/zhu-yuan-lab/research/neural-crest-stem-cells-and-malignant-peripheral-nerve-sheath-tumor-mpnst

  MPNST, a sarcoma arising from the neural-crest stem cell lineage in the peripheral nerve, is the leading cause of death for individuals with NF1. […] Inactivation of NF1 drives benign PNF formation by abnormal activation of the RAS-mediated MEK-ERK/MAPK signaling pathway. […] However, premalignant ANFs carry additional genetic alterations at the CDKN2A locus, which encodes two tumor suppressor genes, p16INK4A and p14ARF (p19Arf in mice). […] Thus, the CDKN2A/ARF-MDM2-p53 regulatory axis is the major tumor suppressive pathway(s) that inhibits the malignant transformation of benign PNFs. […] In addition to the loss of NF1 and CDKN2A, more than half of MPNSTs also harbor additional oncogenic driver mutations, in components of the POLYCOMB REPRESSIVE COMPLEX 2 (PRC2), most frequently SUZ12 or EED.

• #56 Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8774267/

  Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas (STS) with nerve sheath differentiation and a tendency to metastasize. Although occurring at an incidence of 0.001% in the general population, they are relatively common in individuals with neurofibromatosis type 1 (NF1), for whom the lifetime risk approaches 10%. […] MPNSTs may arise de novo from a peripheral nerve OR as a malignant transformation of a pre-existing benign nerve sheath tumor especially neurofibromas. […] MPNSTs are most often characterized by the second variety of mutations specifically by loss of function of the tumor suppressor gene NF1. […] Although bi-allelic NF1 inactivation or mutation appears necessary for MPNST development, it does not seem sufficient. […] Therefore, one potential model for MPNST development proposes that bi-allelic NF1 loss occurs in nerve-sheath precursor cells, resulting in benign neurofibroma formation.

• #57 Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

  https://www.mdpi.com/2227-9067/9/1/38

  Although bi-allelic NF1 inactivation or mutation appears necessary for MPNST development, it does not seem sufficient. […] Therefore, one potential model for MPNST development proposes that bi-allelic NF1 loss occurs in nerve-sheath precursor cells, resulting in benign neurofibroma formation. […] Patients with NF1 possess only a single functional copy of the NF1 gene (e.g., the “first hit”), with loss of the second copy acting as an oncogenic “second hit” and thereby allowing constitutive activation of this pathway. […] A particular characteristic of NF1 is the extreme heterogeneity of its clinical manifestations, which may vary wildly even among members of the same kindred. […] Although many MPNSTs are therefore sporadic, a diagnosis of NF1 is the primary known risk factor. […] Moreover, among those patients with NF1, a family history of NF1 and MPNST appears to be associated with an approximately three-fold greater risk of developing an MPNST in that patient.

• #58 Neural-crest Stem Cells and Malignant Peripheral Nerve Sheath Tumor (MPNST) | Zhu (Yuan) Lab | UT Southwestern, Dallas, Texas

  https://labs.utsouthwestern.edu/zhu-yuan-lab/research/neural-crest-stem-cells-and-malignant-peripheral-nerve-sheath-tumor-mpnst

  MPNST, a sarcoma arising from the neural-crest stem cell lineage in the peripheral nerve, is the leading cause of death for individuals with NF1. […] Inactivation of NF1 drives benign PNF formation by abnormal activation of the RAS-mediated MEK-ERK/MAPK signaling pathway. […] However, premalignant ANFs carry additional genetic alterations at the CDKN2A locus, which encodes two tumor suppressor genes, p16INK4A and p14ARF (p19Arf in mice). […] Thus, the CDKN2A/ARF-MDM2-p53 regulatory axis is the major tumor suppressive pathway(s) that inhibits the malignant transformation of benign PNFs. […] In addition to the loss of NF1 and CDKN2A, more than half of MPNSTs also harbor additional oncogenic driver mutations, in components of the POLYCOMB REPRESSIVE COMPLEX 2 (PRC2), most frequently SUZ12 or EED.

• #59 Neural-crest Stem Cells and Malignant Peripheral Nerve Sheath Tumor (MPNST) | Zhu (Yuan) Lab | UT Southwestern, Dallas, Texas

  https://labs.utsouthwestern.edu/zhu-yuan-lab/research/neural-crest-stem-cells-and-malignant-peripheral-nerve-sheath-tumor-mpnst

  MPNST, a sarcoma arising from the neural-crest stem cell lineage in the peripheral nerve, is the leading cause of death for individuals with NF1. […] Inactivation of NF1 drives benign PNF formation by abnormal activation of the RAS-mediated MEK-ERK/MAPK signaling pathway. […] However, premalignant ANFs carry additional genetic alterations at the CDKN2A locus, which encodes two tumor suppressor genes, p16INK4A and p14ARF (p19Arf in mice). […] Thus, the CDKN2A/ARF-MDM2-p53 regulatory axis is the major tumor suppressive pathway(s) that inhibits the malignant transformation of benign PNFs. […] In addition to the loss of NF1 and CDKN2A, more than half of MPNSTs also harbor additional oncogenic driver mutations, in components of the POLYCOMB REPRESSIVE COMPLEX 2 (PRC2), most frequently SUZ12 or EED.

• #60 Neural-crest Stem Cells and Malignant Peripheral Nerve Sheath Tumor (MPNST) | Zhu (Yuan) Lab | UT Southwestern, Dallas, Texas

  https://labs.utsouthwestern.edu/zhu-yuan-lab/research/neural-crest-stem-cells-and-malignant-peripheral-nerve-sheath-tumor-mpnst

  MPNST, a sarcoma arising from the neural-crest stem cell lineage in the peripheral nerve, is the leading cause of death for individuals with NF1. […] Inactivation of NF1 drives benign PNF formation by abnormal activation of the RAS-mediated MEK-ERK/MAPK signaling pathway. […] However, premalignant ANFs carry additional genetic alterations at the CDKN2A locus, which encodes two tumor suppressor genes, p16INK4A and p14ARF (p19Arf in mice). […] Thus, the CDKN2A/ARF-MDM2-p53 regulatory axis is the major tumor suppressive pathway(s) that inhibits the malignant transformation of benign PNFs. […] In addition to the loss of NF1 and CDKN2A, more than half of MPNSTs also harbor additional oncogenic driver mutations, in components of the POLYCOMB REPRESSIVE COMPLEX 2 (PRC2), most frequently SUZ12 or EED.

• #61 The CoREST complex is a therapeutic vulnerability in malignant peripheral nerve sheath tumors | Scientific Reports

  https://www.nature.com/articles/s41598-025-94517-w

  Malignant peripheral nerve sheath tumor (MPNST) is a highly aggressive sarcoma that may be seen in patients with neurofibromatosis type 1 (NF1) or occur sporadically. […] MPNSTs frequently harbor inactivating driver mutations in the PRC2 epigenetic repressor complex suggesting epigenetic therapies may represent a specific vulnerability in these tumors. […] MPNSTs frequently possess inactivating mutations in genes associated with polycomb repressor complex 2 (PRC2) suggesting that epigenetic approaches to therapy may prove successful. […] Despite convincing evidence that epigenetic therapies including BET bromodomain inhibitors and HDAC inhibitors may prove useful in patients with MPNST, clinical studies have not demonstrated successful responses to date largely due to the narrow therapeutic window of such drugs in solid tumors as well as acquired resistance mechanisms to such therapies.

• #62 Neural-crest Stem Cells and Malignant Peripheral Nerve Sheath Tumor (MPNST) | Zhu (Yuan) Lab | UT Southwestern, Dallas, Texas

  https://labs.utsouthwestern.edu/zhu-yuan-lab/research/neural-crest-stem-cells-and-malignant-peripheral-nerve-sheath-tumor-mpnst

  We will investigate the cellular and molecular mechanisms underlying the sequential loss of these three tumor suppressor genes – NF1, CDKN2A, and EED – in the transformation of a developing nerve cell in the neural-crest stem cell/Schwann cell lineages into benign, premalignant and malignant tumors, respectively.

• #63

  https://link.springer.com/article/10.1007/s11523-024-01078-5

  Malignant peripheral sheath tumor (MPNST) is a rare, aggressive form of soft-tissue sarcoma that presents a unique set of diagnostic and treatment challenges and is associated with major unmet treatment medical needs. […] MPNST has an incidence of 1:100,000 in the general population and 1:3500 among patients with the inherited condition of neurofibromatosis-1. […] Highly copy-number aberrant and enriched in chromosome 8, MPNSTs have a complex molecular pathogenesis that likely involves the interplay of multiple signaling pathways, including Ras/AKT/mTOR/MAPK, EGFR, p53, PTEN, and PRC2, as well as factors in the tumor microenvironment. […] Despite advances in our understanding of the genetics and molecular biology of MPNST, further research is warranted to: (1) unravel the complex pathogenesis of this condition; (2) improve diagnostic yield; (3) delineate the appropriate roles of chemotherapy and radiation; and (4) develop a targeted therapy (or combination of such treatments) that is well tolerated and prolongs survival.

• #64 The CoREST complex is a therapeutic vulnerability in malignant peripheral nerve sheath tumors | Scientific Reports

  https://www.nature.com/articles/s41598-025-94517-w

  Malignant peripheral nerve sheath tumor (MPNST) is a highly aggressive sarcoma that may be seen in patients with neurofibromatosis type 1 (NF1) or occur sporadically. […] MPNSTs frequently harbor inactivating driver mutations in the PRC2 epigenetic repressor complex suggesting epigenetic therapies may represent a specific vulnerability in these tumors. […] MPNSTs frequently possess inactivating mutations in genes associated with polycomb repressor complex 2 (PRC2) suggesting that epigenetic approaches to therapy may prove successful. […] Despite convincing evidence that epigenetic therapies including BET bromodomain inhibitors and HDAC inhibitors may prove useful in patients with MPNST, clinical studies have not demonstrated successful responses to date largely due to the narrow therapeutic window of such drugs in solid tumors as well as acquired resistance mechanisms to such therapies.

• #65

  https://link.springer.com/article/10.1007/s11523-024-01078-5

  Malignant peripheral sheath tumor (MPNST) is a rare, aggressive form of soft-tissue sarcoma that presents a unique set of diagnostic and treatment challenges and is associated with major unmet treatment medical needs. […] MPNST has an incidence of 1:100,000 in the general population and 1:3500 among patients with the inherited condition of neurofibromatosis-1. […] Highly copy-number aberrant and enriched in chromosome 8, MPNSTs have a complex molecular pathogenesis that likely involves the interplay of multiple signaling pathways, including Ras/AKT/mTOR/MAPK, EGFR, p53, PTEN, and PRC2, as well as factors in the tumor microenvironment. […] Despite advances in our understanding of the genetics and molecular biology of MPNST, further research is warranted to: (1) unravel the complex pathogenesis of this condition; (2) improve diagnostic yield; (3) delineate the appropriate roles of chemotherapy and radiation; and (4) develop a targeted therapy (or combination of such treatments) that is well tolerated and prolongs survival.

• #66 A Rare Case of Malignant Peripheral Nerve Sheath Tumor in Neck and Role of VMAT Radiotherapy

  https://www.ijhns.com/abstractArticleContentBrowse/IJHNS/31747/JPJ/fullText

  Malignant peripheral nerve sheath tumor (MPNST) is a rare and aggressive variety of sarcoma. It usually arises from peripheral nerves or cells of the peripheral nerve sheath, like Schwann cells, perineural fibroblast, or endoneurial fibroblast. It constitutes 510% of soft tissue sarcomas, of which, only 816% are found in the head and neck region. They are usually found in patients with NF-1, but also can arise sporadically. They have a high rate of local recurrence and rapid disease progression leading to very poor prognosis despite aggressive therapy and complete resection. […] The mitogen-activated protein kinase (MAPK) pathway, phosphatidylinositol 3-kinases/mouse strain activated kinase (AK) thymoma/(mechanistic) target of rapamycin (PI3K/AKT/mTOR) pathway, and TP53 mutation are some of the major contributors of development of MPNST. About 10% of MPNST arise due to previous irradiation, most commonly associated with irradiation of breast cancer and lymphoma. Such MPNSTs have a poorer prognosis.

• #67

  https://link.springer.com/article/10.1007/s11523-024-01078-5

  Malignant peripheral sheath tumor (MPNST) is a rare, aggressive form of soft-tissue sarcoma that presents a unique set of diagnostic and treatment challenges and is associated with major unmet treatment medical needs. […] MPNST has an incidence of 1:100,000 in the general population and 1:3500 among patients with the inherited condition of neurofibromatosis-1. […] Highly copy-number aberrant and enriched in chromosome 8, MPNSTs have a complex molecular pathogenesis that likely involves the interplay of multiple signaling pathways, including Ras/AKT/mTOR/MAPK, EGFR, p53, PTEN, and PRC2, as well as factors in the tumor microenvironment. […] Despite advances in our understanding of the genetics and molecular biology of MPNST, further research is warranted to: (1) unravel the complex pathogenesis of this condition; (2) improve diagnostic yield; (3) delineate the appropriate roles of chemotherapy and radiation; and (4) develop a targeted therapy (or combination of such treatments) that is well tolerated and prolongs survival.

• #68

  https://link.springer.com/article/10.1007/s11523-024-01078-5

  Malignant peripheral sheath tumor (MPNST) is a rare, aggressive form of soft-tissue sarcoma that presents a unique set of diagnostic and treatment challenges and is associated with major unmet treatment medical needs. […] MPNST has an incidence of 1:100,000 in the general population and 1:3500 among patients with the inherited condition of neurofibromatosis-1. […] Highly copy-number aberrant and enriched in chromosome 8, MPNSTs have a complex molecular pathogenesis that likely involves the interplay of multiple signaling pathways, including Ras/AKT/mTOR/MAPK, EGFR, p53, PTEN, and PRC2, as well as factors in the tumor microenvironment. […] Despite advances in our understanding of the genetics and molecular biology of MPNST, further research is warranted to: (1) unravel the complex pathogenesis of this condition; (2) improve diagnostic yield; (3) delineate the appropriate roles of chemotherapy and radiation; and (4) develop a targeted therapy (or combination of such treatments) that is well tolerated and prolongs survival.

• #69 A GFP-Tagged Gross Deletion on Chromosome 1 Causes Malignant Peripheral Nerve Sheath Tumors and Carcinomas in Zebrafish | PLOS One

  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0145178

  Loss of NF1 and p53 are the most frequent gene alterations, and the majority of MPNSTs show a gene expression signature indicating p53 inactivation. […] Nevertheless, the molecular bases of this malignant transformation are still poorly understood. […] In zebrafish, malignant neoplasms resembling human MPNST have been described in a number of mutant lines and designated as zMPNST (zebrafish MPNSTs). […] Inactivating mutations have been reported in 17 of 28 ribosomal protein (rp) genes, in tp53, in 3 major mismatch repair (mmr) genes and in NF2a and predisposes zebrafish to MPNSTs. […] The deletion is embryonic lethal in homozygotes and developmentally inconsequential in heterozygotes. […] Importantly, we observed the development of zMPNSTs and abdominal carcinomas with high frequency in adult Tg(-8.5nkx2.2a:GFP)ia2 fish.

• #70

  https://link.springer.com/article/10.1007/s11523-024-01078-5

  Malignant peripheral sheath tumor (MPNST) is a rare, aggressive form of soft-tissue sarcoma that presents a unique set of diagnostic and treatment challenges and is associated with major unmet treatment medical needs. […] MPNST has an incidence of 1:100,000 in the general population and 1:3500 among patients with the inherited condition of neurofibromatosis-1. […] Highly copy-number aberrant and enriched in chromosome 8, MPNSTs have a complex molecular pathogenesis that likely involves the interplay of multiple signaling pathways, including Ras/AKT/mTOR/MAPK, EGFR, p53, PTEN, and PRC2, as well as factors in the tumor microenvironment. […] Despite advances in our understanding of the genetics and molecular biology of MPNST, further research is warranted to: (1) unravel the complex pathogenesis of this condition; (2) improve diagnostic yield; (3) delineate the appropriate roles of chemotherapy and radiation; and (4) develop a targeted therapy (or combination of such treatments) that is well tolerated and prolongs survival.

• #71

  https://link.springer.com/article/10.1007/s11523-024-01078-5

  Malignant peripheral sheath tumor (MPNST) is a rare, aggressive form of soft-tissue sarcoma that presents a unique set of diagnostic and treatment challenges and is associated with major unmet treatment medical needs. […] MPNST has an incidence of 1:100,000 in the general population and 1:3500 among patients with the inherited condition of neurofibromatosis-1. […] Highly copy-number aberrant and enriched in chromosome 8, MPNSTs have a complex molecular pathogenesis that likely involves the interplay of multiple signaling pathways, including Ras/AKT/mTOR/MAPK, EGFR, p53, PTEN, and PRC2, as well as factors in the tumor microenvironment. […] Despite advances in our understanding of the genetics and molecular biology of MPNST, further research is warranted to: (1) unravel the complex pathogenesis of this condition; (2) improve diagnostic yield; (3) delineate the appropriate roles of chemotherapy and radiation; and (4) develop a targeted therapy (or combination of such treatments) that is well tolerated and prolongs survival.

• #72 The CoREST complex is a therapeutic vulnerability in malignant peripheral nerve sheath tumors | Scientific Reports

  https://www.nature.com/articles/s41598-025-94517-w

  Malignant peripheral nerve sheath tumor (MPNST) is a highly aggressive sarcoma that may be seen in patients with neurofibromatosis type 1 (NF1) or occur sporadically. […] MPNSTs frequently harbor inactivating driver mutations in the PRC2 epigenetic repressor complex suggesting epigenetic therapies may represent a specific vulnerability in these tumors. […] MPNSTs frequently possess inactivating mutations in genes associated with polycomb repressor complex 2 (PRC2) suggesting that epigenetic approaches to therapy may prove successful. […] Despite convincing evidence that epigenetic therapies including BET bromodomain inhibitors and HDAC inhibitors may prove useful in patients with MPNST, clinical studies have not demonstrated successful responses to date largely due to the narrow therapeutic window of such drugs in solid tumors as well as acquired resistance mechanisms to such therapies.

• #73

  https://link.springer.com/article/10.1007/s11523-024-01078-5

  A history of radiation exposure is present in approximately 10-13% of MPNST cases, with a typical latency period exceeding 16 years. […] NF1-associated plexiform neurofibromas have an approximately 10% risk of malignant transformation, with a higher overall risk in more centrally located neoplasms of the torso and proximal limbs as well as large nerve trunks. […] Loss of NF1 gene expression is considered a necessary but not sufficient condition for MPNST development; other cooperating genetic (and epigenetic) events are required. […] A complex network of signaling pathways underlies the oncogenesis and progression of MPNST. These diverse pathways may open avenues for the development of targeted pharmacotherapies. […] AXL is a receptor tyrosine kinase associated with the survival, growth, and metastasis of MPNST cells.

• #74

  https://link.springer.com/article/10.1007/s11523-024-01078-5

  The combination of TYK2 and MEK inhibition has also shown promising in vivo effects in a preclinical model. […] MPNSTs exhibit intermediate (to poor) chemosensitivity. […] Despite multiple cellular and molecular leads (biomarkers), no single driving pathogenetic event has been identified, and no particular targeted therapy has emerged as a clearly superior regimen against MPNST.

• #75 A GFP-Tagged Gross Deletion on Chromosome 1 Causes Malignant Peripheral Nerve Sheath Tumors and Carcinomas in Zebrafish | PLOS One

  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0145178

  Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive soft-tissue sarcomas, characterized by complex karyotypes. […] The molecular bases of such malignancy are poorly understood and efficient targeted molecular therapies are currently lacking. […] MPNSTs account for 510% of all soft-tissue sarcomas and usually arise from peripheral nerves. […] In humans they occur sporadically or associated with neurofibromatosis type 1, representing the leading cause of mortality in this disease. […] The high recurrence rate (up to 40%), the tendency to metastasize (two-thirds of the cases) and the limited sensitivity to chemo and radiation therapy make MPNSTs highly aggressive tumors with a poor prognosis. […] MPNSTs have complex karyotypes, with massive aneuploidy and heterogeneity.

• #76 Malignant Peripheral Nerve Sheath Tumors

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3926794/

  The large number of molecular aberrations associated with MPNST in both preclinical and clinical studies across a variety of platforms is, on the other hand, not in doubt; MPNST is a genomically complex disease. […] Although relatively similar molecular mechanisms are involved in the pathogenesis of sporadic MPNST, which comprise approximately 40% of all MPNST, there are some distinct differences between these tumors and the NF1-associated variety. […] The remaining 10% of MPNSTs arise secondary to previous irradiation and account for about 5% of radiotherapy (RT)-induced sarcomas, which arise most frequently in the setting of external beam RT for breast cancer or lymphoma. […] The true prognostic impact of NF1 syndrome in MPNST remains somewhat in flux. Several large series report significantly worse outcomes for MPNST arising in the setting of NF1 compared with sporadic disease, with inferior responses to cytotoxic chemotherapy and 5-year survivals that are up to 50% worse. […] The complexity of ras signaling is an obvious target but has proved a nettlesome signaling pathway to target to date, although downstream elements such as MEK may be more easily inhibited.

• #77 A GFP-Tagged Gross Deletion on Chromosome 1 Causes Malignant Peripheral Nerve Sheath Tumors and Carcinomas in Zebrafish | PLOS One

  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0145178

  Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive soft-tissue sarcomas, characterized by complex karyotypes. […] The molecular bases of such malignancy are poorly understood and efficient targeted molecular therapies are currently lacking. […] MPNSTs account for 510% of all soft-tissue sarcomas and usually arise from peripheral nerves. […] In humans they occur sporadically or associated with neurofibromatosis type 1, representing the leading cause of mortality in this disease. […] The high recurrence rate (up to 40%), the tendency to metastasize (two-thirds of the cases) and the limited sensitivity to chemo and radiation therapy make MPNSTs highly aggressive tumors with a poor prognosis. […] MPNSTs have complex karyotypes, with massive aneuploidy and heterogeneity.

• #78

  https://link.springer.com/article/10.1007/s11523-024-01078-5

  Malignant peripheral sheath tumor (MPNST) is a rare, aggressive form of soft-tissue sarcoma that presents a unique set of diagnostic and treatment challenges and is associated with major unmet treatment medical needs. […] MPNST has an incidence of 1:100,000 in the general population and 1:3500 among patients with the inherited condition of neurofibromatosis-1. […] Highly copy-number aberrant and enriched in chromosome 8, MPNSTs have a complex molecular pathogenesis that likely involves the interplay of multiple signaling pathways, including Ras/AKT/mTOR/MAPK, EGFR, p53, PTEN, and PRC2, as well as factors in the tumor microenvironment. […] Despite advances in our understanding of the genetics and molecular biology of MPNST, further research is warranted to: (1) unravel the complex pathogenesis of this condition; (2) improve diagnostic yield; (3) delineate the appropriate roles of chemotherapy and radiation; and (4) develop a targeted therapy (or combination of such treatments) that is well tolerated and prolongs survival.

• #79

  https://link.springer.com/article/10.1007/s11523-024-01078-5

  Malignant peripheral sheath tumor (MPNST) is a rare, aggressive form of soft-tissue sarcoma that presents a unique set of diagnostic and treatment challenges and is associated with major unmet treatment medical needs. […] MPNST has an incidence of 1:100,000 in the general population and 1:3500 among patients with the inherited condition of neurofibromatosis-1. […] Highly copy-number aberrant and enriched in chromosome 8, MPNSTs have a complex molecular pathogenesis that likely involves the interplay of multiple signaling pathways, including Ras/AKT/mTOR/MAPK, EGFR, p53, PTEN, and PRC2, as well as factors in the tumor microenvironment. […] Despite advances in our understanding of the genetics and molecular biology of MPNST, further research is warranted to: (1) unravel the complex pathogenesis of this condition; (2) improve diagnostic yield; (3) delineate the appropriate roles of chemotherapy and radiation; and (4) develop a targeted therapy (or combination of such treatments) that is well tolerated and prolongs survival.

• #80 Malignant Peripheral Nerve Sheath Tumors

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3926794/

  The large number of molecular aberrations associated with MPNST in both preclinical and clinical studies across a variety of platforms is, on the other hand, not in doubt; MPNST is a genomically complex disease. […] Although relatively similar molecular mechanisms are involved in the pathogenesis of sporadic MPNST, which comprise approximately 40% of all MPNST, there are some distinct differences between these tumors and the NF1-associated variety. […] The remaining 10% of MPNSTs arise secondary to previous irradiation and account for about 5% of radiotherapy (RT)-induced sarcomas, which arise most frequently in the setting of external beam RT for breast cancer or lymphoma. […] The true prognostic impact of NF1 syndrome in MPNST remains somewhat in flux. Several large series report significantly worse outcomes for MPNST arising in the setting of NF1 compared with sporadic disease, with inferior responses to cytotoxic chemotherapy and 5-year survivals that are up to 50% worse. […] The complexity of ras signaling is an obvious target but has proved a nettlesome signaling pathway to target to date, although downstream elements such as MEK may be more easily inhibited.

• #81

  https://link.springer.com/article/10.1007/s11523-024-01078-5

  The combination of TYK2 and MEK inhibition has also shown promising in vivo effects in a preclinical model. […] MPNSTs exhibit intermediate (to poor) chemosensitivity. […] Despite multiple cellular and molecular leads (biomarkers), no single driving pathogenetic event has been identified, and no particular targeted therapy has emerged as a clearly superior regimen against MPNST.

• #82 Malignant peripheral nerve sheath tumours in inherited disease | Clinical Sarcoma Research | Full Text

  https://clinicalsarcomaresearch.biomedcentral.com/articles/10.1186/2045-3329-2-17

  Malignant peripheral nerve sheath tumours (MPNST) are rare tumours known to occur at high frequency in neurofibromatosis 1 (NF1), but may also occur in other cancer prone syndromes. […] MPNST is associated with schwannomatosis and TP53 mutations and is confirmed at high frequency in NF1. […] The presence of three confirmed TP53 mutation carriers with MPNST makes a link with germline TP53 mutations and Li Fraumeni syndrome very likely. […] In conclusion MPNST appears to occur at increased frequency in schwannomatosis and in those with germline TP53 mutations as well as those with NF1.

• #83 Peripheral nerve tumors – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/peripheral-nerve-tumors/symptoms-causes/syc-20355070

  It’s not clear why most peripheral nerve tumors develop. Some are linked to known inherited syndromes, such as neurofibromatosis (types 1 and 2) and schwannomatosis. Others may be caused by changes in a gene. […] Peripheral nerve tumors are more common in people who have: […] Neurofibromatosis (types 1 and 2) and schwannomatosis. In these disorders, tumors develop on or near the nerves throughout the body. There are often multiple tumors. They can lead to a variety of symptoms depending on where they are in the body. These tumors are usually not cancerous. […] A history of radiation treatment. A person who was exposed to radiation is at higher risk of developing peripheral nerve tumors years later.

• #84 Malignant peripheral nerve sheath tumours in inherited disease | Clinical Sarcoma Research | Full Text

  https://clinicalsarcomaresearch.biomedcentral.com/articles/10.1186/2045-3329-2-17

  Malignant peripheral nerve sheath tumours (MPNST) are rare tumours known to occur at high frequency in neurofibromatosis 1 (NF1), but may also occur in other cancer prone syndromes. […] MPNST is associated with schwannomatosis and TP53 mutations and is confirmed at high frequency in NF1. […] The presence of three confirmed TP53 mutation carriers with MPNST makes a link with germline TP53 mutations and Li Fraumeni syndrome very likely. […] In conclusion MPNST appears to occur at increased frequency in schwannomatosis and in those with germline TP53 mutations as well as those with NF1.

• #85 Peripheral nerve tumors – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/peripheral-nerve-tumors/symptoms-causes/syc-20355070

  It’s not clear why most peripheral nerve tumors develop. Some are linked to known inherited syndromes, such as neurofibromatosis (types 1 and 2) and schwannomatosis. Others may be caused by changes in a gene. […] Peripheral nerve tumors are more common in people who have: […] Neurofibromatosis (types 1 and 2) and schwannomatosis. In these disorders, tumors develop on or near the nerves throughout the body. There are often multiple tumors. They can lead to a variety of symptoms depending on where they are in the body. These tumors are usually not cancerous. […] A history of radiation treatment. A person who was exposed to radiation is at higher risk of developing peripheral nerve tumors years later.

• #86 Malignant peripheral nerve sheath tumours in inherited disease | Clinical Sarcoma Research | Full Text

  https://clinicalsarcomaresearch.biomedcentral.com/articles/10.1186/2045-3329-2-17

  Malignant peripheral nerve sheath tumours (MPNST) are rare tumours known to occur at high frequency in neurofibromatosis 1 (NF1), but may also occur in other cancer prone syndromes. […] MPNST is associated with schwannomatosis and TP53 mutations and is confirmed at high frequency in NF1. […] The presence of three confirmed TP53 mutation carriers with MPNST makes a link with germline TP53 mutations and Li Fraumeni syndrome very likely. […] In conclusion MPNST appears to occur at increased frequency in schwannomatosis and in those with germline TP53 mutations as well as those with NF1.

• #87 Peripheral nerve tumors – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/peripheral-nerve-tumors/symptoms-causes/syc-20355070

  It’s not clear why most peripheral nerve tumors develop. Some are linked to known inherited syndromes, such as neurofibromatosis (types 1 and 2) and schwannomatosis. Others may be caused by changes in a gene. […] Peripheral nerve tumors are more common in people who have: […] Neurofibromatosis (types 1 and 2) and schwannomatosis. In these disorders, tumors develop on or near the nerves throughout the body. There are often multiple tumors. They can lead to a variety of symptoms depending on where they are in the body. These tumors are usually not cancerous. […] A history of radiation treatment. A person who was exposed to radiation is at higher risk of developing peripheral nerve tumors years later.

• #88 Nervous system: Peripheral nerve sheath tumors

  https://atlasgeneticsoncology.org/solid-tumor/5094/nervous-system-peripheral-nerve-sheath-tumors

  The etiology of PNSTs is usually unknown. However, several hereditary disorders are known to predispose to benign and malignant PNSTs, notably neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2), both of which are inherited in an autosomal dominant fashion. […] The incidence of MPNST is in general rare, but half of all cases arise in NF1 patients. […] The basis for MPNST occurring in the setting of NF1 is presumed to be biallelic inactivation of the NF1 gene.

• #89 Malignant peripheral nerve sheath tumours in inherited disease | Clinical Sarcoma Research | Full Text

  https://clinicalsarcomaresearch.biomedcentral.com/articles/10.1186/2045-3329-2-17

  Malignant peripheral nerve sheath tumours (MPNST) are rare tumours known to occur at high frequency in neurofibromatosis 1 (NF1), but may also occur in other cancer prone syndromes. […] MPNST is associated with schwannomatosis and TP53 mutations and is confirmed at high frequency in NF1. […] The presence of three confirmed TP53 mutation carriers with MPNST makes a link with germline TP53 mutations and Li Fraumeni syndrome very likely. […] In conclusion MPNST appears to occur at increased frequency in schwannomatosis and in those with germline TP53 mutations as well as those with NF1.

• #90 Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

  https://www.mdpi.com/2227-9067/9/1/38

  Although bi-allelic NF1 inactivation or mutation appears necessary for MPNST development, it does not seem sufficient. […] Therefore, one potential model for MPNST development proposes that bi-allelic NF1 loss occurs in nerve-sheath precursor cells, resulting in benign neurofibroma formation. […] Patients with NF1 possess only a single functional copy of the NF1 gene (e.g., the “first hit”), with loss of the second copy acting as an oncogenic “second hit” and thereby allowing constitutive activation of this pathway. […] A particular characteristic of NF1 is the extreme heterogeneity of its clinical manifestations, which may vary wildly even among members of the same kindred. […] Although many MPNSTs are therefore sporadic, a diagnosis of NF1 is the primary known risk factor. […] Moreover, among those patients with NF1, a family history of NF1 and MPNST appears to be associated with an approximately three-fold greater risk of developing an MPNST in that patient.

• #91 Malignant peripheral nerve sheath tumor – Wikipedia

  https://en.wikipedia.org/wiki/Malignant_peripheral_nerve_sheath_tumor

  A malignant peripheral nerve sheath tumor (MPNST) is a form of cancer of the connective tissue surrounding peripheral nerves. […] About half the cases are diagnosed in people with neurofibromatosis; the lifetime risk for an MPNST in patients with neurofibromatosis type 1 is 813%. […] Soft tissue sarcomas have been linked within families, so it is hypothesized that neurofibrosarcoma may be genetic, although researchers still do not know the exact cause of the disease. […] Evidence supporting this hypothesis includes loss of heterozygosity on the 17p chromosome. […] The p53 (a tumor suppressor gene in the normal population) genome on 17p in neurofibrosarcoma patients is mutated, increasing the probability of cancer. […] The normal p53 gene will regulate cell growth and inhibit any uncontrollable cell growth in the healthy population; since p53 is inactivated in neurofibrosarcoma patients, they are much more susceptible to developing tumors.

• #92 Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

  https://www.mdpi.com/2227-9067/9/1/38

  Although bi-allelic NF1 inactivation or mutation appears necessary for MPNST development, it does not seem sufficient. […] Therefore, one potential model for MPNST development proposes that bi-allelic NF1 loss occurs in nerve-sheath precursor cells, resulting in benign neurofibroma formation. […] Patients with NF1 possess only a single functional copy of the NF1 gene (e.g., the “first hit”), with loss of the second copy acting as an oncogenic “second hit” and thereby allowing constitutive activation of this pathway. […] A particular characteristic of NF1 is the extreme heterogeneity of its clinical manifestations, which may vary wildly even among members of the same kindred. […] Although many MPNSTs are therefore sporadic, a diagnosis of NF1 is the primary known risk factor. […] Moreover, among those patients with NF1, a family history of NF1 and MPNST appears to be associated with an approximately three-fold greater risk of developing an MPNST in that patient.

• #93 Malignant peripheral nerve sheath tumor – Wikipedia

  https://en.wikipedia.org/wiki/Malignant_peripheral_nerve_sheath_tumor

  A malignant peripheral nerve sheath tumor (MPNST) is a form of cancer of the connective tissue surrounding peripheral nerves. […] About half the cases are diagnosed in people with neurofibromatosis; the lifetime risk for an MPNST in patients with neurofibromatosis type 1 is 813%. […] Soft tissue sarcomas have been linked within families, so it is hypothesized that neurofibrosarcoma may be genetic, although researchers still do not know the exact cause of the disease. […] Evidence supporting this hypothesis includes loss of heterozygosity on the 17p chromosome. […] The p53 (a tumor suppressor gene in the normal population) genome on 17p in neurofibrosarcoma patients is mutated, increasing the probability of cancer. […] The normal p53 gene will regulate cell growth and inhibit any uncontrollable cell growth in the healthy population; since p53 is inactivated in neurofibrosarcoma patients, they are much more susceptible to developing tumors.

• #94 Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

  https://www.mdpi.com/2227-9067/9/1/38

  Although bi-allelic NF1 inactivation or mutation appears necessary for MPNST development, it does not seem sufficient. […] Therefore, one potential model for MPNST development proposes that bi-allelic NF1 loss occurs in nerve-sheath precursor cells, resulting in benign neurofibroma formation. […] Patients with NF1 possess only a single functional copy of the NF1 gene (e.g., the “first hit”), with loss of the second copy acting as an oncogenic “second hit” and thereby allowing constitutive activation of this pathway. […] A particular characteristic of NF1 is the extreme heterogeneity of its clinical manifestations, which may vary wildly even among members of the same kindred. […] Although many MPNSTs are therefore sporadic, a diagnosis of NF1 is the primary known risk factor. […] Moreover, among those patients with NF1, a family history of NF1 and MPNST appears to be associated with an approximately three-fold greater risk of developing an MPNST in that patient.

• #95 Nerve Sheath Tumors | The National Canine Cancer Foundation

  https://wearethecure.org/learn-more-about-canine-cancer/canine-cancer-library/nerve-sheath-tumors/

  Malignant peripheral nerve sheath tumors (MPNSTs) are cancerous in nature. […] Although the etiology is unknown, they are believed to develop in areas around former injury. […] It is thought that during the process of repair, tumorogenesis takes place. However, there is no published information supporting the fact.

• #96 Nerve Sheath Tumor in Dogs

  https://www.dogcancer.com/articles/types-of-dog-cancer/nerve-sheath-tumor-in-dogs/

  Peripheral nerve sheath tumors in dogs are uncommon, but can be very serious, depending on the type and location of the tumor. […] There is no known specific cause for canine peripheral nerve sheath tumors. Like all cancers, this is a multifactorial disease, which means that many things have to go wrong for it to occur. […] In humans, exposure to radiation therapy and genetics may increase the risk of peripheral nerve sheath tumors, but we do not know if this is the same in dogs. […] Unfortunately, there is no known way to prevent peripheral nerve sheath tumors in dogs.

• #97 Nerve Sheath Tumors | The National Canine Cancer Foundation

  https://wearethecure.org/learn-more-about-canine-cancer/canine-cancer-library/nerve-sheath-tumors/

  Malignant peripheral nerve sheath tumors (MPNSTs) are cancerous in nature. […] Although the etiology is unknown, they are believed to develop in areas around former injury. […] It is thought that during the process of repair, tumorogenesis takes place. However, there is no published information supporting the fact.

• #98 What Are Malignant Peripheral Nerve Sheath Tumors?

  https://www.rwjbh.org/treatment-care/neuroscience/neurology/conditions/malignant-peripheral-nerve-sheath-tumors/

  Malignant peripheral nerve sheath tumors, also known as neurofibrosarcomas, are found in the protective lining, or myelin sheath, surrounding the peripheral (outside) nerves of the spinal cord the nerves that reach out to the rest of the body. These rare cancerous tumors occur most commonly in the muscle, fat, nerves, and other soft tissue of the torso, arms, or legs. […] The exact causes of these tumors arent known, but they begin when a cell in the sheath develops a DNA mutation. They grow and divide much faster than normal. The excess of cells forms invasive, spreadable tumors. […] Malignant peripheral nerve sheath tumors are most common in young adults and middle-aged adults, and more than half are found in people who have neurofibromatosis 1 (a non-cancerous condition that causes bone deformities).

• #99 Malignant Peripheral Nerve Sheath Tumors: Latest Concepts in Disease Pathogenesis and Clinical Management

  https://www.mdpi.com/2072-6694/15/4/1077

  Several studies over the last decade have indicated that NF1-associated MPNSTs typically begin as plexiform neurofibroma (PN) and atypical neurofibromatous neoplasm of unknown biological potential (ANNUBP). […] The probability of malignant progression to MPNST is 10–15%. […] In summary, previous studies have found numerous risk factors associated with the onset of MPNST. NF1 is the most important factor in 50% of MPNST patients. The history of therapeutic irradiation can also increase the risk of MPSNT. Possession of PN and ANNUBP has malignant potential to cause MPNST development. Additionally, aging is an important risk factor because MPNST development takes a long time.

• #100 What Are Malignant Peripheral Nerve Sheath Tumors?

  https://www.rwjbh.org/treatment-care/neuroscience/neurology/conditions/malignant-peripheral-nerve-sheath-tumors/

  Malignant peripheral nerve sheath tumors, also known as neurofibrosarcomas, are found in the protective lining, or myelin sheath, surrounding the peripheral (outside) nerves of the spinal cord the nerves that reach out to the rest of the body. These rare cancerous tumors occur most commonly in the muscle, fat, nerves, and other soft tissue of the torso, arms, or legs. […] The exact causes of these tumors arent known, but they begin when a cell in the sheath develops a DNA mutation. They grow and divide much faster than normal. The excess of cells forms invasive, spreadable tumors. […] Malignant peripheral nerve sheath tumors are most common in young adults and middle-aged adults, and more than half are found in people who have neurofibromatosis 1 (a non-cancerous condition that causes bone deformities).

• #101 Malignant Peripheral Nerve Sheath Tumors: Differentiation Patterns and Immunohistochemical Features – A Mini-Review and Our New Findings

  https://www.jcancer.org/v03p0303.htm

  Malignant peripheral nerve sheath tumors (MPNST) represent a group of highly heterogeneous human malignancies often with multiple histological origins, divergent differentiation patterns, and diverse immunohistochemical presentations. […] Malignant peripheral nerve sheath tumor (MPNST), also known as Malignant schwannoma, Neurofibrosarcoma, or Neurosarcoma, is derived from Schwann cells or pluripotent cells of the neural crest. […] One half to two thirds arises from neurofibromas, often of plexiform neurofibromas or in the setting of neurofibromatosis type I, which occur frequently on the head or neck. The other MPNSTs arise de novo, which usually involve the peripheral nerves in the buttocks or thighs, mostly the sciatic nerve. […] MPNST is a tumor associated with an aggressive behavior and its prognosis is poor with death occurring in 63%, usually with 2-year of diagnosis.

• #102 Pathology Outlines – Malignant peripheral nerve sheath tumor (MPNST)

  https://www.pathologyoutlines.com/topic/softtissuempnst.html

  Malignant neoplasm arising from peripheral nerve […] May arise from a preexisting nerve sheath tumor in neurofibromatosis type 1 (NF1) or in the setting of prior radiation therapy […] In the absence of association with NF1 or radiation, diagnosis is challenging and based on histologic and immunohistochemical features suggesting Schwannian differentiation […] MPNST can occur in the following settings: Sporadic (approximately 50%) […] In neurofibromatosis type 1 (40 – 50%) […] In the setting of prior radiation therapy (10%) […] Germline mutations in NF1 predispose to the development of peripheral nerve sheath neoplasms in patients with type 1 neurofibromatosis […] In the setting of NF1, lesions often arise from plexiform neurofibroma […] Radiation therapy predisposes to the development of secondary sarcomas through repeated DNA damage and defective repair

• #103

  https://www.advocatehealth.com/health-services/brain-spine-institute/peripheral-nerve-tumors/malignant-peripheral-nerve-sheath-tumor

  Malignant peripheral nerve sheath tumors are exceedingly rare. […] We dont know what causes malignant peripheral nerve sheath tumors. Recent research has discovered links to genes in these cancers that may lead to more effective therapies. […] People who have a genetic condition called neurofibromatosis type 1 make up about 50% of those diagnosed with a malignant peripheral nerve sheath tumor. Having had previous exposure to radiation, either environmental or through radiation treatment, is another risk factor. […] Some malignant peripheral nerve sheath tumors happen randomly without any known risk factors.

• #104 Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8774267/

  The other primary known risk factor for MPNST development is radiation exposure, typically in the context of a secondary malignant neoplasm occurring following radiotherapy. […] In most series, patients with either a diagnosis of NF1 or prior radiotherapy have shown a worse overall survival compared to those with sporadic MPNSTs likely due to the greater propensity towards metastases and/or local invasion demonstrated by tumors in these patients. […] However, the presence of NF1 itself does not directly appear to be the causative risk factor for these poorer outcomes instead, patients with NF1 tend to have larger tumors, which are more challenging to fully resect. […] A particular characteristic of NF1 is the extreme heterogeneity of its clinical manifestations, which may vary wildly even among members of the same kindred. […] Although many MPNSTs are therefore sporadic, a diagnosis of NF1 is the primary known risk factor.

• #105 Malignant Peripheral Nerve Sheath Tumors

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3926794/

  The large number of molecular aberrations associated with MPNST in both preclinical and clinical studies across a variety of platforms is, on the other hand, not in doubt; MPNST is a genomically complex disease. […] Although relatively similar molecular mechanisms are involved in the pathogenesis of sporadic MPNST, which comprise approximately 40% of all MPNST, there are some distinct differences between these tumors and the NF1-associated variety. […] The remaining 10% of MPNSTs arise secondary to previous irradiation and account for about 5% of radiotherapy (RT)-induced sarcomas, which arise most frequently in the setting of external beam RT for breast cancer or lymphoma. […] The true prognostic impact of NF1 syndrome in MPNST remains somewhat in flux. Several large series report significantly worse outcomes for MPNST arising in the setting of NF1 compared with sporadic disease, with inferior responses to cytotoxic chemotherapy and 5-year survivals that are up to 50% worse. […] The complexity of ras signaling is an obvious target but has proved a nettlesome signaling pathway to target to date, although downstream elements such as MEK may be more easily inhibited.

• #106 Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8774267/

  The other primary known risk factor for MPNST development is radiation exposure, typically in the context of a secondary malignant neoplasm occurring following radiotherapy. […] In most series, patients with either a diagnosis of NF1 or prior radiotherapy have shown a worse overall survival compared to those with sporadic MPNSTs likely due to the greater propensity towards metastases and/or local invasion demonstrated by tumors in these patients. […] However, the presence of NF1 itself does not directly appear to be the causative risk factor for these poorer outcomes instead, patients with NF1 tend to have larger tumors, which are more challenging to fully resect. […] A particular characteristic of NF1 is the extreme heterogeneity of its clinical manifestations, which may vary wildly even among members of the same kindred. […] Although many MPNSTs are therefore sporadic, a diagnosis of NF1 is the primary known risk factor.

• #107 Recurrent malignant peripheral nerve sheath tumor presenting as an asymptomatic intravenous thrombus extending to the heart: a case report | World Journal of Surgical Oncology | Full Text

  https://wjso.biomedcentral.com/articles/10.1186/s12957-021-02473-2

  Malignant peripheral nerve sheath tumor (MPNST) is a rare soft tissue sarcoma mainly treated via surgical resection. […] Malignant peripheral nerve sheath tumors (MPNSTs) are rare, accounting for approximately 5% of all soft tissue sarcomas. […] Previous studies have reported that 20-50% of patients with MPNST also have neurofibromatosis type 1 (NF1), which is an autosomal dominant condition with a birth incidence of approximately 1 in 2500. […] Patients with NF1 typically manifest caf-au-lait macules in the first decade of life and cutaneous neurofibromas during adolescence, and they carry an increased risk of developing malignancies. […] MPNSTs occur in patients with NF1, with a cumulative lifetime risk of up to 10%. […] Patients with NF1-MPNST reportedly have lower survival rates and generally worse prognoses than those with sporadic MPNST.

• #108 Recurrent malignant peripheral nerve sheath tumor presenting as an asymptomatic intravenous thrombus extending to the heart: a case report | World Journal of Surgical Oncology | Full Text

  https://wjso.biomedcentral.com/articles/10.1186/s12957-021-02473-2

  In the absence of metastases, the 5-year overall survival rates are 63% for sporadic MPNST and 33% for NF1-MPNST. […] Furthermore, MPNSTs are traditionally chemotherapy insensitive. […] Since the clinical benefits of adjuvant therapy such as radiation or chemotherapy are limited in patients with MPNST, surgical resection is the usual treatment strategy. […] Microscopic venous invasion during the initial surgery most likely led to an intravenous recurrence. […] A clinicopathological study of 24 patients with MPNST demonstrated vascular invasion as a poor prognostic factor. […] However, few reports are available on recurrent MPNSTs with intravascular invasion. […] If histology suggests venous invasion, as it did in our case, there is a potential risk of intravenous recurrence and distant metastasis that can progress to a massive tumor thrombus extending to the heart, regardless of the tumor subtype.

• #109 Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8774267/

  The other primary known risk factor for MPNST development is radiation exposure, typically in the context of a secondary malignant neoplasm occurring following radiotherapy. […] In most series, patients with either a diagnosis of NF1 or prior radiotherapy have shown a worse overall survival compared to those with sporadic MPNSTs likely due to the greater propensity towards metastases and/or local invasion demonstrated by tumors in these patients. […] However, the presence of NF1 itself does not directly appear to be the causative risk factor for these poorer outcomes instead, patients with NF1 tend to have larger tumors, which are more challenging to fully resect. […] A particular characteristic of NF1 is the extreme heterogeneity of its clinical manifestations, which may vary wildly even among members of the same kindred. […] Although many MPNSTs are therefore sporadic, a diagnosis of NF1 is the primary known risk factor.

• #110 Cauda equina malignant peripheral nerve sheath tumor presenting with subarachnoid hemorrhage: a case report | Neurocirugía (English edition)

  https://www.revistaneurocirugia.com/en-cauda-equina-malignant-peripheral-nerve-articulo-S2529849624000583

  Malignant peripheral nerve sheath tumors (MPNST) are highly malignant soft tissue neoplasms that originate from the mesenchymal cells residing within the nerve sheath, in most cases from Schwann cells. MPNST predominantly affect young people. Patients with MPNST have a poor prognosis with a 5-year survival rate from 16% to 44% with a local recurrence expected in 38-45% of cases. Metastases are also frequent, mainly to the lungs, liver and brain. […] MPNST are a rare entity with an incidence of 0.001% that represent only 5% of all soft-tissue sarcomas. Spinal MPNST correspond to 23% of all cases, with only 6 cases of intradural lumbar MPNST reported in the literature. Their clinical presentation and diagnostic work-up can be misleading due to the symptomatic and imaging overlap with lumbar disc herniation.

• #111 A Rare Case of Malignant Peripheral Nerve Sheath Tumor in Neck and Role of VMAT Radiotherapy

  https://www.ijhns.com/abstractArticleContentBrowse/IJHNS/31747/JPJ/fullText

  The most common sites involved are the nerve roots and bundles in the extremities and pelvis, particularly the sciatic nerve. Its rarely found in the head and neck region. The lung is the most common site of metastasis, seen in 50% of patients. […] The 5-year survival rate of MPNST is 1550%. They are aggressive, have a high incidence of metastasis, and have a poor prognosis. Tumor size 5 cm, p53 expression, AKT, and TOR pathway activation (identified immunohistochemically), and mesenchymal epithelial transition activation are associated with poor prognosis. […] Due to its large size and aggressive nature, adjuvant radiation therapy (RT) has been shown to decrease local recurrence. In advanced or metastatic cases, some response is shown with doxorubicin and ifosfamide, which overall has poor survival.

• #112 A Discussion of Malignant Peripheral Nerve Sheath Tumors (MPNSTs) – Neurofibromatosis Program

  https://www.uab.edu/medicine/nfprogram/blog/blog-archive/a-discussion-of-malignant-peripheral-nerve-sheath-tumors-mpnsts

  The focus of this months blog post is a discussion of malignant peripheral nerve sheath tumors (MPNSTs), which represent one of the few potentially life-threatening complications of neurofibromatosis type 1. […] Because MPNSTs are very challenging to treat, early diagnosis is critical. MPNSTs can be hard to recognize, and the diagnosis is often late because individuals are either not aware the tumors are there or do not recognize changes in neurofibromas that should be investigated. […] The development of MPNSTs from tumors such as plexiform neurofibromas occurs by the progressive accumulation of genetic changes that are characteristic of cancer. […] The genetic changes in MPNSTs make these tumors difficult to control. […] Treatment of MPNSTs usually involves surgery to resect the tumor, if possible. […] Current NF clinical trials are evaluating chemotherapy as well as other therapeutics targeting genetic changes in the tumor. […] In conclusion, because MPNSTs are difficult to treat, early detection is critically important.

• #113 Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma | eLife

  https://elifesciences.org/articles/74238

  Malignant peripheral nerve sheath tumors (MPNST) are the deadliest cancer that arises in individuals diagnosed with neurofibromatosis and account for nearly 5% of the 15,000 soft tissue sarcomas diagnosed in the United States each year. […] Primary risk factors for developing MPNST include existing plexiform neurofibromas (PN), prior radiotherapy treatment, and expansive germline mutations involving the entire NF1 gene and surrounding genes. […] Bi-allelic loss of NF1 is not sufficient for malignant transformation of PN to MPNST. […] Additional mutations or copy number alterations of genes such as TP53, SUZ12, EGFR, CDKN2A, and TERT that are often not present in benign PN suggest that these alterations represent advanced progression to atypical neurofibroma (AN) and MPNST. […] Liquid biopsies that assay for mutations or aneuploidy in circulating tumor DNA (ctDNA) represent an attractive, minimally invasive option that could be performed at each longitudinal patient visit. […] Mutations in polycomb repressive complex 2 (PRC2) subunits such as SUZ12 and EED are found in nearly 70% of MPNST. […] Malignant transformation of a plexiform neurofibroma to MPSNT can occur over years.

• #114 A Discussion of Malignant Peripheral Nerve Sheath Tumors (MPNSTs) – Neurofibromatosis Program

  https://www.uab.edu/medicine/nfprogram/blog/blog-archive/a-discussion-of-malignant-peripheral-nerve-sheath-tumors-mpnsts

  The focus of this months blog post is a discussion of malignant peripheral nerve sheath tumors (MPNSTs), which represent one of the few potentially life-threatening complications of neurofibromatosis type 1. […] Because MPNSTs are very challenging to treat, early diagnosis is critical. MPNSTs can be hard to recognize, and the diagnosis is often late because individuals are either not aware the tumors are there or do not recognize changes in neurofibromas that should be investigated. […] The development of MPNSTs from tumors such as plexiform neurofibromas occurs by the progressive accumulation of genetic changes that are characteristic of cancer. […] The genetic changes in MPNSTs make these tumors difficult to control. […] Treatment of MPNSTs usually involves surgery to resect the tumor, if possible. […] Current NF clinical trials are evaluating chemotherapy as well as other therapeutics targeting genetic changes in the tumor. […] In conclusion, because MPNSTs are difficult to treat, early detection is critically important.

• #115 A Discussion of Malignant Peripheral Nerve Sheath Tumors (MPNSTs) – Neurofibromatosis Program

  https://www.uab.edu/medicine/nfprogram/blog/blog-archive/a-discussion-of-malignant-peripheral-nerve-sheath-tumors-mpnsts

  The focus of this months blog post is a discussion of malignant peripheral nerve sheath tumors (MPNSTs), which represent one of the few potentially life-threatening complications of neurofibromatosis type 1. […] Because MPNSTs are very challenging to treat, early diagnosis is critical. MPNSTs can be hard to recognize, and the diagnosis is often late because individuals are either not aware the tumors are there or do not recognize changes in neurofibromas that should be investigated. […] The development of MPNSTs from tumors such as plexiform neurofibromas occurs by the progressive accumulation of genetic changes that are characteristic of cancer. […] The genetic changes in MPNSTs make these tumors difficult to control. […] Treatment of MPNSTs usually involves surgery to resect the tumor, if possible. […] Current NF clinical trials are evaluating chemotherapy as well as other therapeutics targeting genetic changes in the tumor. […] In conclusion, because MPNSTs are difficult to treat, early detection is critically important.

• #116 Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma | eLife

  https://elifesciences.org/articles/74238

  Malignant peripheral nerve sheath tumors (MPNST) are the deadliest cancer that arises in individuals diagnosed with neurofibromatosis and account for nearly 5% of the 15,000 soft tissue sarcomas diagnosed in the United States each year. […] Primary risk factors for developing MPNST include existing plexiform neurofibromas (PN), prior radiotherapy treatment, and expansive germline mutations involving the entire NF1 gene and surrounding genes. […] Bi-allelic loss of NF1 is not sufficient for malignant transformation of PN to MPNST. […] Additional mutations or copy number alterations of genes such as TP53, SUZ12, EGFR, CDKN2A, and TERT that are often not present in benign PN suggest that these alterations represent advanced progression to atypical neurofibroma (AN) and MPNST. […] Liquid biopsies that assay for mutations or aneuploidy in circulating tumor DNA (ctDNA) represent an attractive, minimally invasive option that could be performed at each longitudinal patient visit. […] Mutations in polycomb repressive complex 2 (PRC2) subunits such as SUZ12 and EED are found in nearly 70% of MPNST. […] Malignant transformation of a plexiform neurofibroma to MPSNT can occur over years.

• #117 Nerve sheath tumor – Wikipedia

  https://en.wikipedia.org/wiki/Nerve_sheath_tumor

  A malignant peripheral nerve sheath tumor is a cancerous peripheral nerve sheath tumor, which is frequently resistant to conventional treatments. […] Neurofibromas and malignant peripheral nerve sheath tumors can be difficult to distinguish from each other and may require additional testing, including PET scans (18FDG-PET). […] Complete surgical resection is the current treatment of choice for malignant spinal nerve sheath tumors. […] Chemotherapy for malignant spinal nerve sheath tumors has shown mixed results and is typically only used in patients in which surgery is not an option, or with aggressive or metastatic disease.

• #118 Recurrent malignant peripheral nerve sheath tumor presenting as an asymptomatic intravenous thrombus extending to the heart: a case report | World Journal of Surgical Oncology | Full Text

  https://wjso.biomedcentral.com/articles/10.1186/s12957-021-02473-2

  In the absence of metastases, the 5-year overall survival rates are 63% for sporadic MPNST and 33% for NF1-MPNST. […] Furthermore, MPNSTs are traditionally chemotherapy insensitive. […] Since the clinical benefits of adjuvant therapy such as radiation or chemotherapy are limited in patients with MPNST, surgical resection is the usual treatment strategy. […] Microscopic venous invasion during the initial surgery most likely led to an intravenous recurrence. […] A clinicopathological study of 24 patients with MPNST demonstrated vascular invasion as a poor prognostic factor. […] However, few reports are available on recurrent MPNSTs with intravascular invasion. […] If histology suggests venous invasion, as it did in our case, there is a potential risk of intravenous recurrence and distant metastasis that can progress to a massive tumor thrombus extending to the heart, regardless of the tumor subtype.

• #119 Nerve sheath tumor – Wikipedia

  https://en.wikipedia.org/wiki/Nerve_sheath_tumor

  A malignant peripheral nerve sheath tumor is a cancerous peripheral nerve sheath tumor, which is frequently resistant to conventional treatments. […] Neurofibromas and malignant peripheral nerve sheath tumors can be difficult to distinguish from each other and may require additional testing, including PET scans (18FDG-PET). […] Complete surgical resection is the current treatment of choice for malignant spinal nerve sheath tumors. […] Chemotherapy for malignant spinal nerve sheath tumors has shown mixed results and is typically only used in patients in which surgery is not an option, or with aggressive or metastatic disease.

• #120

  https://www.advocatehealth.com/health-services/brain-spine-institute/peripheral-nerve-tumors

  A small percentage of neurofibromas and schwannomas can become malignant peripheral nerve sheath tumors (MPNST). These tumors are fast-growing and often grow on nerves in the legs, arms or pelvis. They can be resistant to chemotherapy treatment and often recur after treatment. […] Malignant peripheral nerve sheath tumor treatment usually includes cancer surgery to remove as much of the tumor as possible. In extreme cases, surgery for an MPNST may require partial amputation of an affected limb.

• #121 Recurrent malignant peripheral nerve sheath tumor presenting as an asymptomatic intravenous thrombus extending to the heart: a case report | World Journal of Surgical Oncology | Full Text

  https://wjso.biomedcentral.com/articles/10.1186/s12957-021-02473-2

  In the absence of metastases, the 5-year overall survival rates are 63% for sporadic MPNST and 33% for NF1-MPNST. […] Furthermore, MPNSTs are traditionally chemotherapy insensitive. […] Since the clinical benefits of adjuvant therapy such as radiation or chemotherapy are limited in patients with MPNST, surgical resection is the usual treatment strategy. […] Microscopic venous invasion during the initial surgery most likely led to an intravenous recurrence. […] A clinicopathological study of 24 patients with MPNST demonstrated vascular invasion as a poor prognostic factor. […] However, few reports are available on recurrent MPNSTs with intravascular invasion. […] If histology suggests venous invasion, as it did in our case, there is a potential risk of intravenous recurrence and distant metastasis that can progress to a massive tumor thrombus extending to the heart, regardless of the tumor subtype.

• #122 Nerve sheath tumor – Wikipedia

  https://en.wikipedia.org/wiki/Nerve_sheath_tumor

  A malignant peripheral nerve sheath tumor is a cancerous peripheral nerve sheath tumor, which is frequently resistant to conventional treatments. […] Neurofibromas and malignant peripheral nerve sheath tumors can be difficult to distinguish from each other and may require additional testing, including PET scans (18FDG-PET). […] Complete surgical resection is the current treatment of choice for malignant spinal nerve sheath tumors. […] Chemotherapy for malignant spinal nerve sheath tumors has shown mixed results and is typically only used in patients in which surgery is not an option, or with aggressive or metastatic disease.

• #123 Recurrent malignant peripheral nerve sheath tumor presenting as an asymptomatic intravenous thrombus extending to the heart: a case report | World Journal of Surgical Oncology | Full Text

  https://wjso.biomedcentral.com/articles/10.1186/s12957-021-02473-2

  In the absence of metastases, the 5-year overall survival rates are 63% for sporadic MPNST and 33% for NF1-MPNST. […] Furthermore, MPNSTs are traditionally chemotherapy insensitive. […] Since the clinical benefits of adjuvant therapy such as radiation or chemotherapy are limited in patients with MPNST, surgical resection is the usual treatment strategy. […] Microscopic venous invasion during the initial surgery most likely led to an intravenous recurrence. […] A clinicopathological study of 24 patients with MPNST demonstrated vascular invasion as a poor prognostic factor. […] However, few reports are available on recurrent MPNSTs with intravascular invasion. […] If histology suggests venous invasion, as it did in our case, there is a potential risk of intravenous recurrence and distant metastasis that can progress to a massive tumor thrombus extending to the heart, regardless of the tumor subtype.

• #124 Malignant peripheral nerve sheath tumour (MPNST) | Soft tissue sarcoma | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/soft-tissue-sarcoma/types/malignant-schwannoma

  Malignant peripheral nerve sheath tumours are a type of peripheral nerve sheath tumour. These cancers begin in the layer (nerve sheath) that cover the peripheral nerves. MPNST are rare in the general population. It can happen in people with neurofibromatosis type 1(NF1). […] Malignant peripheral nerve sheath tumours can be difficult to treat. […] Malignant peripheral nerve sheath tumours don’t respond very well to chemotherapy. Chemotherapy may be used to try to shrink the tumour or slow its growth, but it is usually unlikely to cure it. […] A malignant peripheral nerve sheath tumour can come back in the same place. This is called local recurrence.

• #125 Cauda equina malignant peripheral nerve sheath tumor presenting with subarachnoid hemorrhage: a case report | Neurocirugía (English edition)

  https://www.revistaneurocirugia.com/en-cauda-equina-malignant-peripheral-nerve-articulo-S2529849624000583

  The mainstay of treatment in MPNST is surgical resection. An aggressive resection provides local control and has been related with better outcomes. In cases involving extensive bone removal for complete tumoral resection, spinal fixation is necessary to mitigate the risk of postoperative deformity. Adjuvant radiotherapy has been recommended to improve local control. However, regardless of gross total resection and adjuvant radiotherapy, the reported 5-year survival rates vary from 16% to 44%.

• #126 A Rare Case of Malignant Peripheral Nerve Sheath Tumor in Neck and Role of VMAT Radiotherapy

  https://www.ijhns.com/abstractArticleContentBrowse/IJHNS/31747/JPJ/fullText

  The most common sites involved are the nerve roots and bundles in the extremities and pelvis, particularly the sciatic nerve. Its rarely found in the head and neck region. The lung is the most common site of metastasis, seen in 50% of patients. […] The 5-year survival rate of MPNST is 1550%. They are aggressive, have a high incidence of metastasis, and have a poor prognosis. Tumor size 5 cm, p53 expression, AKT, and TOR pathway activation (identified immunohistochemically), and mesenchymal epithelial transition activation are associated with poor prognosis. […] Due to its large size and aggressive nature, adjuvant radiation therapy (RT) has been shown to decrease local recurrence. In advanced or metastatic cases, some response is shown with doxorubicin and ifosfamide, which overall has poor survival.

• #127 A Rare Case of Malignant Peripheral Nerve Sheath Tumor in Neck and Role of VMAT Radiotherapy

  https://www.ijhns.com/abstractArticleContentBrowse/IJHNS/31747/JPJ/fullText

  There is limited data on radiotherapy in patients of MPNST separately, even though radiotherapy can be given as a definitive treatment in unresectable cases and for palliation of symptoms in metastatic cases. VMAT radiotherapy aims at giving radiation to the targeted area without affecting nearby critical organs or unnecessary irradiation of surrounding areas which may again lead to the development of RT-induced sarcomas in already susceptible patients like those with NF-1.

• #128 The CoREST complex is a therapeutic vulnerability in malignant peripheral nerve sheath tumors | Scientific Reports

  https://www.nature.com/articles/s41598-025-94517-w

  In this study, we explore the role of the CoREST epigenetic repressor complex in regulating tumorigenesis in MPNST. […] Inhibition of the LHC complex by corin leads to a significant reduction in cell proliferation, with significantly greater effects than the HDACi, entinostat in all MPNST cell lines evaluated; however, NF1+/ PRC2+ tumor cells demonstrate decreased sensitivity to corin versus NF1-/PCR2- tumor cells. […] Additionally, we find that corin induces apoptosis in MPNST cell lines regardless of their PRC2 mutational status; this is in contrast to the relative resistance of PRC2+ MPNST cells to apoptosis in the setting of treatment with entinostat and other HDACi therapies. […] Thus, the anti-invasive properties associated with corin treatment of MPNST cells may be particularly worthwhile in PRC2-inactivated tumors.

• #129

  https://www.advocatehealth.com/health-services/brain-spine-institute/peripheral-nerve-tumors

  A small percentage of neurofibromas and schwannomas can become malignant peripheral nerve sheath tumors (MPNST). These tumors are fast-growing and often grow on nerves in the legs, arms or pelvis. They can be resistant to chemotherapy treatment and often recur after treatment. […] Malignant peripheral nerve sheath tumor treatment usually includes cancer surgery to remove as much of the tumor as possible. In extreme cases, surgery for an MPNST may require partial amputation of an affected limb.

• #130 Recurrent malignant peripheral nerve sheath tumor presenting as an asymptomatic intravenous thrombus extending to the heart: a case report | World Journal of Surgical Oncology | Full Text

  https://wjso.biomedcentral.com/articles/10.1186/s12957-021-02473-2

  MPNSTs derived from NF1 often occur in the major nerves, and radical wide resection of the affected nerves results in severe neurological deficits that lead to considerable physical impairment. […] The frequency of amputation is reported to be 32% in deep and high-grade MPNSTs. […] Amputation is more frequent in MPNSTs than in other sarcomas because MPNSTs often occur in the major nerves, and amputation is recommended as a curative surgery to prevent recurrence.

• #131

  https://link.springer.com/article/10.1007/s11523-024-01078-5

  Malignant peripheral sheath tumor (MPNST) is a rare, aggressive form of soft-tissue sarcoma that presents a unique set of diagnostic and treatment challenges and is associated with major unmet treatment medical needs. […] MPNST has an incidence of 1:100,000 in the general population and 1:3500 among patients with the inherited condition of neurofibromatosis-1. […] Highly copy-number aberrant and enriched in chromosome 8, MPNSTs have a complex molecular pathogenesis that likely involves the interplay of multiple signaling pathways, including Ras/AKT/mTOR/MAPK, EGFR, p53, PTEN, and PRC2, as well as factors in the tumor microenvironment. […] Despite advances in our understanding of the genetics and molecular biology of MPNST, further research is warranted to: (1) unravel the complex pathogenesis of this condition; (2) improve diagnostic yield; (3) delineate the appropriate roles of chemotherapy and radiation; and (4) develop a targeted therapy (or combination of such treatments) that is well tolerated and prolongs survival.

• #132 Neural-crest Stem Cells and Malignant Peripheral Nerve Sheath Tumor (MPNST) | Zhu (Yuan) Lab | UT Southwestern, Dallas, Texas

  https://labs.utsouthwestern.edu/zhu-yuan-lab/research/neural-crest-stem-cells-and-malignant-peripheral-nerve-sheath-tumor-mpnst

  MPNST, a sarcoma arising from the neural-crest stem cell lineage in the peripheral nerve, is the leading cause of death for individuals with NF1. […] Inactivation of NF1 drives benign PNF formation by abnormal activation of the RAS-mediated MEK-ERK/MAPK signaling pathway. […] However, premalignant ANFs carry additional genetic alterations at the CDKN2A locus, which encodes two tumor suppressor genes, p16INK4A and p14ARF (p19Arf in mice). […] Thus, the CDKN2A/ARF-MDM2-p53 regulatory axis is the major tumor suppressive pathway(s) that inhibits the malignant transformation of benign PNFs. […] In addition to the loss of NF1 and CDKN2A, more than half of MPNSTs also harbor additional oncogenic driver mutations, in components of the POLYCOMB REPRESSIVE COMPLEX 2 (PRC2), most frequently SUZ12 or EED.

• #133 Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8774267/

  The other primary known risk factor for MPNST development is radiation exposure, typically in the context of a secondary malignant neoplasm occurring following radiotherapy. […] In most series, patients with either a diagnosis of NF1 or prior radiotherapy have shown a worse overall survival compared to those with sporadic MPNSTs likely due to the greater propensity towards metastases and/or local invasion demonstrated by tumors in these patients. […] However, the presence of NF1 itself does not directly appear to be the causative risk factor for these poorer outcomes instead, patients with NF1 tend to have larger tumors, which are more challenging to fully resect. […] A particular characteristic of NF1 is the extreme heterogeneity of its clinical manifestations, which may vary wildly even among members of the same kindred. […] Although many MPNSTs are therefore sporadic, a diagnosis of NF1 is the primary known risk factor.

• #134

  https://www.advocatehealth.com/health-services/brain-spine-institute/peripheral-nerve-tumors/malignant-peripheral-nerve-sheath-tumor

  Malignant peripheral nerve sheath tumors are exceedingly rare. […] We dont know what causes malignant peripheral nerve sheath tumors. Recent research has discovered links to genes in these cancers that may lead to more effective therapies. […] People who have a genetic condition called neurofibromatosis type 1 make up about 50% of those diagnosed with a malignant peripheral nerve sheath tumor. Having had previous exposure to radiation, either environmental or through radiation treatment, is another risk factor. […] Some malignant peripheral nerve sheath tumors happen randomly without any known risk factors.

• #135 Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma | eLife

  https://elifesciences.org/articles/74238

  Malignant peripheral nerve sheath tumors (MPNST) are the deadliest cancer that arises in individuals diagnosed with neurofibromatosis and account for nearly 5% of the 15,000 soft tissue sarcomas diagnosed in the United States each year. […] Primary risk factors for developing MPNST include existing plexiform neurofibromas (PN), prior radiotherapy treatment, and expansive germline mutations involving the entire NF1 gene and surrounding genes. […] Bi-allelic loss of NF1 is not sufficient for malignant transformation of PN to MPNST. […] Additional mutations or copy number alterations of genes such as TP53, SUZ12, EGFR, CDKN2A, and TERT that are often not present in benign PN suggest that these alterations represent advanced progression to atypical neurofibroma (AN) and MPNST. […] Liquid biopsies that assay for mutations or aneuploidy in circulating tumor DNA (ctDNA) represent an attractive, minimally invasive option that could be performed at each longitudinal patient visit. […] Mutations in polycomb repressive complex 2 (PRC2) subunits such as SUZ12 and EED are found in nearly 70% of MPNST. […] Malignant transformation of a plexiform neurofibroma to MPSNT can occur over years.

• #136 Malignant peripheral nerve sheath tumor | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/malignant-peripheral-nerve-sheath-tumour?lang=us

  Malignant peripheral nerve sheath tumors (MPNSTs) are forms of peripheral nerve sheath tumors occurring either de novo or arising from pre-existing tumors (e.g. neurofibromas, schwannomas etc.). Approximately half of such tumors are seen in individuals with neurofibromatosis type I (NF1), in such cases arising from pre-existing neurofibromas. […] Malignant peripheral nerve sheath tumors can arise in a number of different situations: de novo, de-differentiation, radiation therapy-associated. […] Most MPNSTs demonstrate inactivation of a number of genes: NF1, CDKN2A, and PRC2. […] It is worth noting that this grading is in contrast many benign neurogenic tumors (e.g. neurofibromas, schwannomas and perineuriomas) that sometimes can give rise to MPNST are given a grade of 1 in the WHO classification of CNS tumors.

• #137 Malignant Peripheral Nerve Sheath Tumors: Latest Concepts in Disease Pathogenesis and Clinical Management

  https://www.mdpi.com/2072-6694/15/4/1077

  Several studies over the last decade have indicated that NF1-associated MPNSTs typically begin as plexiform neurofibroma (PN) and atypical neurofibromatous neoplasm of unknown biological potential (ANNUBP). […] The probability of malignant progression to MPNST is 10–15%. […] In summary, previous studies have found numerous risk factors associated with the onset of MPNST. NF1 is the most important factor in 50% of MPNST patients. The history of therapeutic irradiation can also increase the risk of MPSNT. Possession of PN and ANNUBP has malignant potential to cause MPNST development. Additionally, aging is an important risk factor because MPNST development takes a long time.

• #138 Neural-crest Stem Cells and Malignant Peripheral Nerve Sheath Tumor (MPNST) | Zhu (Yuan) Lab | UT Southwestern, Dallas, Texas

  https://labs.utsouthwestern.edu/zhu-yuan-lab/research/neural-crest-stem-cells-and-malignant-peripheral-nerve-sheath-tumor-mpnst

  MPNST, a sarcoma arising from the neural-crest stem cell lineage in the peripheral nerve, is the leading cause of death for individuals with NF1. […] Inactivation of NF1 drives benign PNF formation by abnormal activation of the RAS-mediated MEK-ERK/MAPK signaling pathway. […] However, premalignant ANFs carry additional genetic alterations at the CDKN2A locus, which encodes two tumor suppressor genes, p16INK4A and p14ARF (p19Arf in mice). […] Thus, the CDKN2A/ARF-MDM2-p53 regulatory axis is the major tumor suppressive pathway(s) that inhibits the malignant transformation of benign PNFs. […] In addition to the loss of NF1 and CDKN2A, more than half of MPNSTs also harbor additional oncogenic driver mutations, in components of the POLYCOMB REPRESSIVE COMPLEX 2 (PRC2), most frequently SUZ12 or EED.

• #139

  https://link.springer.com/article/10.1007/s11523-024-01078-5

  Malignant peripheral sheath tumor (MPNST) is a rare, aggressive form of soft-tissue sarcoma that presents a unique set of diagnostic and treatment challenges and is associated with major unmet treatment medical needs. […] MPNST has an incidence of 1:100,000 in the general population and 1:3500 among patients with the inherited condition of neurofibromatosis-1. […] Highly copy-number aberrant and enriched in chromosome 8, MPNSTs have a complex molecular pathogenesis that likely involves the interplay of multiple signaling pathways, including Ras/AKT/mTOR/MAPK, EGFR, p53, PTEN, and PRC2, as well as factors in the tumor microenvironment. […] Despite advances in our understanding of the genetics and molecular biology of MPNST, further research is warranted to: (1) unravel the complex pathogenesis of this condition; (2) improve diagnostic yield; (3) delineate the appropriate roles of chemotherapy and radiation; and (4) develop a targeted therapy (or combination of such treatments) that is well tolerated and prolongs survival.

• #140 A Rare Case of Malignant Peripheral Nerve Sheath Tumor in Neck and Role of VMAT Radiotherapy

  https://www.ijhns.com/abstractArticleContentBrowse/IJHNS/31747/JPJ/fullText

  Malignant peripheral nerve sheath tumor (MPNST) is a rare and aggressive variety of sarcoma. It usually arises from peripheral nerves or cells of the peripheral nerve sheath, like Schwann cells, perineural fibroblast, or endoneurial fibroblast. It constitutes 510% of soft tissue sarcomas, of which, only 816% are found in the head and neck region. They are usually found in patients with NF-1, but also can arise sporadically. They have a high rate of local recurrence and rapid disease progression leading to very poor prognosis despite aggressive therapy and complete resection. […] The mitogen-activated protein kinase (MAPK) pathway, phosphatidylinositol 3-kinases/mouse strain activated kinase (AK) thymoma/(mechanistic) target of rapamycin (PI3K/AKT/mTOR) pathway, and TP53 mutation are some of the major contributors of development of MPNST. About 10% of MPNST arise due to previous irradiation, most commonly associated with irradiation of breast cancer and lymphoma. Such MPNSTs have a poorer prognosis.

• #141

  https://link.springer.com/article/10.1007/s11523-024-01078-5

  Malignant peripheral sheath tumor (MPNST) is a rare, aggressive form of soft-tissue sarcoma that presents a unique set of diagnostic and treatment challenges and is associated with major unmet treatment medical needs. […] MPNST has an incidence of 1:100,000 in the general population and 1:3500 among patients with the inherited condition of neurofibromatosis-1. […] Highly copy-number aberrant and enriched in chromosome 8, MPNSTs have a complex molecular pathogenesis that likely involves the interplay of multiple signaling pathways, including Ras/AKT/mTOR/MAPK, EGFR, p53, PTEN, and PRC2, as well as factors in the tumor microenvironment. […] Despite advances in our understanding of the genetics and molecular biology of MPNST, further research is warranted to: (1) unravel the complex pathogenesis of this condition; (2) improve diagnostic yield; (3) delineate the appropriate roles of chemotherapy and radiation; and (4) develop a targeted therapy (or combination of such treatments) that is well tolerated and prolongs survival.

Zobacz więcej